<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Inhaled corticosteroids for the treatment of COVID‐19 - Griesel, M - 2022 | Cochrane Library</title> <meta content="Inhaled corticosteroids for the treatment of COVID‐19 - Griesel, M - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015125/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Inhaled corticosteroids for the treatment of COVID‐19 - Griesel, M - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015125/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015125" name="dc.identifier" scheme="DOI"/> <meta content="Inhaled corticosteroids for the treatment of COVID‐19" name="citation_title"/> <meta content="Mirko Griesel&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Carina Wagner&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Agata Mikolajewska" name="citation_author"/> <meta content="Miriam Stegemann" name="citation_author"/> <meta content="Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin" name="citation_author_institution"/> <meta content="Falk Fichtner" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Maria-Inti Metzendorf" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf" name="citation_author_institution"/> <meta content="Avinash Anil Nair" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Jefferson Daniel" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Anna-Lena Fischer&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Nicole Skoetz&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="nicole.skoetz@uk-koeln.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD015125" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/03/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015125/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015125/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015125/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones; Cause of Death; *COVID-19 Drug Treatment; Respiration, Artificial; SARS-CoV-2" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015125&amp;doi=10.1002/14651858.CD015125&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="xNbeAU8n";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015125\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015125\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015125\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ko","pt","ms","hr","fr","zh_HANS","zh_HANT","ja","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015125",title:"Inhaled corticosteroids for the treatment of COVID\\u201019",firstPublishedDate:"Mar 9, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015125&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015125';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015125/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015125/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015125%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015125/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015125/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015125/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015125/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015125" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015125/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015125" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015125/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015125/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>23123 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015125" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015125/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/appendices#CD015125-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/supinfo/CD015125StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/supinfo/CD015125StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015125/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015125/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015125/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015125/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015125/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Inhaled corticosteroids for the treatment of COVID‐19</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="contributed equally (first author)"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0004">Mirko Griesel</a><sup>a</sup></li> <li class="author custom-tooltip" title="contributed equally (first author)"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0005">Carina Wagner</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0006">Agata Mikolajewska</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0007">Miriam Stegemann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0008">Falk Fichtner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0009">Maria-Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0010">Avinash Anil Nair</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0011">Jefferson Daniel</a></li> <li class="author custom-tooltip" title="contributed equally (last author)"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0012">Anna-Lena Fischer</a><sup>a</sup></li> <li class="author custom-tooltip" title="contributed equally (last author)"><a href="/cdsr/doi/10.1002/14651858.CD015125/information#CD015125-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>Nicole Skoetz</a><sup>a</sup></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015125/information/en#CD015125-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 March 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015125/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015125">https://doi.org/10.1002/14651858.CD015125</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015125-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015125-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015125-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015125-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015125-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015125-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD015125-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015125-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015125-abs-0001" lang="en"> <section id="CD015125-sec-0001"> <h3 class="title" id="CD015125-sec-0001">Background</h3> <p>Inhaled corticosteroids are well established for the long‐term treatment of inflammatory respiratory diseases such as asthma or chronic obstructive pulmonary disease. They have been investigated for the treatment of coronavirus disease 2019 (COVID‐19). The anti‐inflammatory action of inhaled corticosteroids might have the potential to reduce the risk of severe illness resulting from hyperinflammation in COVID‐19. </p> </section> <section id="CD015125-sec-0002"> <h3 class="title" id="CD015125-sec-0002">Objectives</h3> <p>To assess whether inhaled corticosteroids are effective and safe in the treatment of COVID‐19; and to maintain the currency of the evidence, using a living systematic review approach. </p> </section> <section id="CD015125-sec-0003"> <h3 class="title" id="CD015125-sec-0003">Search methods</h3> <p>We searched the Cochrane COVID‐19 Study Register (which includes CENTRAL, PubMed, Embase, ClinicalTrials.gov, WHO ICTRP, and medRxiv), Web of Science (Science Citation Index, Emerging Citation Index), and the WHO COVID‐19 Global literature on coronavirus disease to identify completed and ongoing studies to 7 October 2021. </p> </section> <section id="CD015125-sec-0004"> <h3 class="title" id="CD015125-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) evaluating inhaled corticosteroids for COVID‐19, irrespective of disease severity, age, sex, or ethnicity. </p> <p>We included the following interventions: any type or dose of inhaled corticosteroids. We included the following comparison: inhaled corticosteroids plus standard care versus standard care (with or without placebo). </p> <p>We excluded studies examining nasal or topical steroids.</p> </section> <section id="CD015125-sec-0005"> <h3 class="title" id="CD015125-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodology. For risk of bias assessment, we used the Cochrane RoB 2 tool. We rated the certainty of evidence using the GRADE approach for the outcomes of mortality, admission to hospital or death, symptom resolution, time to symptom resolution, serious adverse events, adverse events, and infections. </p> </section> <section id="CD015125-sec-0006"> <h3 class="title" id="CD015125-sec-0006">Main results</h3> <p><b><i>Inhaled corticosteroids plus standard care versus standard care (with/without placebo)</i> </b> </p> <p><b>People with a confirmed diagnosis of moderate‐to‐severe COVID‐19</b> </p> <p>We found no studies that included people with a confirmed diagnosis of moderate‐to‐severe COVID‐19. </p> <p><b>People with a confirmed diagnosis of asymptomatic SARS‐CoV‐2 infection or mild COVID‐19</b> </p> <p>We included three RCTs allocating 3607 participants, of whom 2490 had confirmed mild COVID‐19. We analysed a subset of the total number of participants recruited to the studies (2171, 52% female) as some trials had a platform design where not all participants were allocated to treatment groups simultaneously. The included studies were community‐based, recruiting people who were able to use inhaler devices to deliver steroids and relied on remote assessment and self‐reporting of outcomes. Most people were older than 50 years and had co‐morbidities such as hypertension, lung disease, or diabetes. The studies were conducted in high‐income countries prior to wide‐scale vaccination programmes. A total of 1057 participants were analysed in the inhaled corticosteroid arm (budesonide: 860 participants; ciclesonide: 197 participants), and 1075 participants in the control arm. No studies included people with asymptomatic SARS‐CoV‐2 infection. </p> <p>With respect to the following outcomes, inhaled corticosteroids compared to standard care: </p> <p>– may result in little to no difference in <i>all‐cause mortality (at up to day 30)</i> (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.22 to 1.67; 2132 participants; low‐certainty evidence). In absolute terms, this means that for every nine deaths per 1000 people not receiving inhaled corticosteroids, there were six deaths per 1000 people who did receive the intervention (95% CI 2 to 16 per 1000 people); </p> <p>– probably reduces <i>admission to hospital or death (at up to 30 days)</i> (RR 0.72, 95% CI 0.51 to 0.99; 2025 participants; moderate‐certainty evidence); </p> <p>– probably increases <i>resolution of all initial symptoms at day 14</i> (RR 1.19, 95% CI 1.09 to 1.30; 1986 participants; moderate‐certainty evidence); </p> <p>– may reduce the <i>duration to symptom resolution (at up to day 30)</i> (by −4.00 days, 95% CI −6.22 to −1.78 less than control group rate of 12 days; 139 participants; low‐certainty evidence); </p> <p>– the evidence is very uncertain about the effect on <i>serious adverse events (during study period)</i> (RR 0.51, 95% CI 0.09 to 2.76; 1586 participants; very low‐certainty evidence); </p> <p>– may result in little to no difference in <i>adverse events (at up to day 30)</i> (RR 0.78, 95% CI 0.47 to 1.31; 400 participants; low‐certainty evidence); </p> <p>– may result in little to no difference in <i>infections (during study period)</i> (RR 0.88, 95% CI 0.30 to 2.58; 400 participants; low‐certainty evidence). </p> <p>As studies did not report outcomes for subgroups (e.g. age, ethnicity, sex), we did not perform subgroup analyses. </p> </section> <section id="CD015125-sec-0007"> <h3 class="title" id="CD015125-sec-0007">Authors' conclusions</h3> <p>In people with confirmed COVID‐19 and mild symptoms who are able to use inhaler devices, we found moderate‐certainty evidence that inhaled corticosteroids probably reduce the combined endpoint of admission to hospital or death and increase the resolution of all initial symptoms at day 14. Low‐certainty evidence suggests that corticosteroids make little to no difference in all‐cause mortality up to day 30 and may decrease the duration to symptom resolution. We do not know whether inhaled corticosteroids increase or decrease serious adverse events due to heterogeneity in the way they were reported across the studies. There is low‐certainty evidence that inhaled corticosteroids may decrease infections. </p> <p>The evidence we identified came from studies in high‐income settings using budesonide and ciclesonide prior to vaccination roll‐outs. </p> <p>We identified a lack of evidence concerning quality of life assessments, serious adverse events, and people with asymptomatic infection or with moderate‐to‐severe COVID‐19. The 10 ongoing and four completed, unpublished RCTs that we identified in trial registries address similar settings and research questions as in the current body of evidence. We expect to incorporate the findings of these studies in future versions of this review. </p> <p>We monitor newly published results of RCTs on inhaled corticosteroids on a weekly basis and will update the review when the evidence or our certainty in the evidence changes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015125-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015125-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015125-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015125-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015125-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015125-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD015125-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD015125-abs-0018">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015125-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015125-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD015125-abs-0021">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD015125-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD015125-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015125-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015125-abs-0017">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015125-abs-0002" lang="en"> <h3>Are inhaled corticosteroids an effective treatment for people with mild COVID‐19?</h3> <p><b>Key messages</b> </p> <p>Inhaled corticosteroids (anti‐inflammatory medicines) given via the oral inhaled route are evaluated for treatment of coronavirus disease 2019 (COVID‐19). </p> <p>We identified three published studies for people with mild disease. Inhaled corticosteroids probably reduce the risk of people going to hospital or death (admission to hospital or death before hospital admission). Inhaled corticosteroids may lower the number of days people have symptoms of mild COVID‐19 and probably increase resolution of COVID‐19 symptoms at day 14. They may make little to no difference in death from any cause, and we do not have enough evidence to know whether they cause serious harms. </p> <p>There are no data for people with COVID‐19 with no symptoms (asymptomatic) or people with moderate‐to‐severe COVID‐19. </p> <p>We found 10 ongoing and four completed unpublished studies. We will update this review when their results become available. </p> <p><b>What are inhaled corticosteroids?</b> </p> <p>Inhaled corticosteroids are medicines that are breathed into the lower airways through an inhaler where they reduce inflammation in the lungs. They are commonly used to treat respiratory diseases like asthma and chronic obstructive pulmonary disease. Long‐term use and incorrect inhaler technique may lead to side effects that include a mouth infection called thrush, a change in voice, and an increased risk of lung infections. Good inhaler technique means the medicine does not stay in the mouth and throat. </p> <p><b>Why are inhaled corticosteroids possible treatments for COVID‐19?</b> </p> <p>COVID‐19 mainly affects the lungs and airways. When the immune system fights the virus, the lungs and airways become inflamed. This inflammation causes breathing difficulties, and the lungs cannot easily move oxygen into the blood and remove carbon dioxide from the blood. </p> <p><b>What did we want to find out?</b> </p> <p>People need more and better treatment options for asymptomatic SARS‐CoV‐2 infection (the virus that causes COVID‐19) or mild, moderate, or severe COVID‐19. We wanted to know if inhaled corticosteroids are an effective and helpful treatment option for COVID‐19 in any setting (for example, home or hospital) and whether they cause unwanted effects. </p> <p>We were interested in:</p> <p>– death from any cause up to day 30, day 60, or longer if reported;</p> <p>– admission to hospital or death within 30 days;</p> <p>– whether symptoms resolved and how fast;</p> <p>– quality of life;</p> <p>– unwanted effects.</p> <p><b>What did we do?</b> </p> <p>We looked for studies where the investigators compared inhaled corticosteroids and usual care to usual care only, sometimes in addition to a dummy medicine that did not contain any active ingredients (placebo) but was given in the same way. To make the comparison least skewed and more fair, patients in the studies must all have had the same random chance (like the flip of a coin) to receive the inhaled corticosteroids or the other treatment. The studies could include people of any age, sex, or ethnicity. </p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>Three studies compared inhaled corticosteroids plus usual care compared to usual care with or without placebo in people with a confirmed diagnosis of mild COVID‐19. These studies analysed 2171 participants mostly older than 50 years and with other medical problems, 52% of them were female, of whom 1057 received inhaled corticosteroids in our analyses. We found no studies that included people with asymptomatic infection or confirmed diagnosis of moderate‐to‐severe COVID‐19. </p> <p>We also found 10 ongoing studies, and four completed studies without published results.</p> <p><b>Main results</b> </p> <p>All studies compared inhaled corticosteroids with usual care or placebo. The studies included only people with a confirmed diagnosis of SARS‐CoV‐2 infection and mild disease. No studies looked at hospitalised people or people with asymptomatic SARS‐CoV‐2 infection. Inhaled corticosteroids </p> <p>– may make little to no difference in death from any cause up to day 30;</p> <p>– probably reduce the risk of admission to hospital or occurrence of death up to day 30; </p> <p>– probably increase resolution of COVID‐19 symptoms at day 14 and may reduce time to symptom resolution. </p> <p>We are very uncertain about a possible difference in serious unwanted effects. Moreover, inhaled corticosteroids may result in little to no difference in the number of any unwanted effects or additional infections. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The studies were conducted in populations from wealthy countries, prior to the roll‐out of COVID‐19 vaccination programmes. We have moderate confidence in the evidence for the outcomes of symptom resolution at day 14 and hospital admission. We have low confidence in the evidence for the effects on deaths from any cause for people with mild COVID‐19 and time to symptom resolution. The confidence in the unwanted or serious unwanted effects and infections is low or very low, because of the differences in the way investigators recorded and reported results. There was no evidence for people with asymptomatic infection or moderate‐to‐severe COVID‐19 who were hospitalised. </p> <p><b>How up to date is this evidence?</b> </p> <p>Our evidence is up‐to‐date to 7 October 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015125-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015125-sec-0095"></div> <h3 class="title" id="CD015125-sec-0096">Implications for practice</h3> <section id="CD015125-sec-0096"> <p>In people with confirmed COVID‐19 and mild symptoms who are able to use inhaler devices, we found moderate‐certainty evidence that inhaled corticosteroids probably reduce the combined endpoint of mortality or hospitalisation and increases symptom resolution at day 14. Low‐certainty evidence suggests that inhaled corticosteroids make little to no difference in all‐cause mortality at up to day 30 and decrease the duration to symptom resolution. </p> <p>Due to heterogeneity in the reporting of serious adverse events across the studies, we do not know whether inhaled corticosteroids increase or decrease the risk of this outcome. There is low‐certainty evidence that inhaled corticosteroids may decrease infections. </p> <p>Most practitioners in family and internal medicine are familiar with prescription, efficacy, adherence, and favourable safety profiles of inhaled corticosteroids in hyperinflammatory pulmonary disease. However, data for use in COVID‐19 are not as clear. Moreover, the data presented in our review only apply directly to a subpopulation of people with COVID‐19 with mild disease and within a group of adults aged 50 years and above who have not been using inhaled corticosteroids. The evidence we identified came from studies in high‐income settings prior to vaccination roll‐out and current variants (delta, omicron) of SARS‐CoV‐2, yet we assume that neither has a relevant effect on the expected benefits and harms. </p> </section> <h3 class="title" id="CD015125-sec-0097">Implications for research</h3> <section id="CD015125-sec-0097"> <p>We noted the lack of safety data for serious adverse events, adverse events, and infections reported by included studies: only one evaluated serious adverse events for 1586 participants, only one randomised controlled trial (RCT) provided adequate information on adverse events and infections for 400 participants. </p> <p>As studies reported a lack of compliance with the treatment, future assessment of patient‐reported experience measures (PREMs) could help to identify further unwanted effects or targets to improve compliance. </p> <p>There was no information related to treatment of participants with asymptomatic SARS‐CoV‐2 infection that could be of special interest in countries with (temporally) reduced medical resources. Also, the use of inhaled corticosteroids for people with moderate‐to‐severe disease has not yet been examined. Studies in more severely ill populations should measure ventilator‐free days, or the occurrence of new invasive mechanical ventilation or death. </p> <p>We suggest there is a need for further research into the impact of inhaled corticosteroids on quality of life in people with COVID‐19 and different dosages or different inhaled corticosteroids. We deem it crucial to use blinding through placebo‐control to reduce the risk of bias. </p> <p>The 10 ongoing and five completed, unpublished RCTs we identified in trial registries address broadly similar questions to those in the published evidence to date. We expect to incorporate the findings of these studies in future versions of this review. </p> <p>In line with our living approach to this work, we will monitor newly published results of RCTs on inhaled corticosteroids on a monthly basis and will update the review when the evidence or our confidence in the evidence changes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015125-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015125-sec-0008"></div> <div class="table" id="CD015125-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Inhaled corticosteroids plus standard care compared to standard care (with or without placebo) for adults with a confirmed diagnosis of mild COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Inhaled corticosteroids plus standard care compared to standard care (with or without placebo) for adults with a confirmed diagnosis of asymptomatic SARS‐CoV‐2 infection or mild COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> inhaled corticosteroids plus standard care </p> <p><b>Comparison:</b> standard care (with or without placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with standard care (with or without placebo)<sup>a</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with inhaled corticosteroids (plus standard care)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: at up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> <p>(2 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.61</b> </p> <p>(0.22 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2132</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids may result in little to no difference in all‐cause mortality up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Admission to hospital or death</b> </p> <p>Follow‐up: at up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> <p>(40 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b> </p> <p>(0.51 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2025</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖</p> <p><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids probably reduce the risk of admission to hospital or death up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom resolution:</b> all initial symptoms resolved </p> <p>at day 14</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>465 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000</p> <p>(507 to 605)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> </p> <p>(1.09 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids probably increase the resolution of all initial symptoms at day 14. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom resolution:</b> duration to symptoms resolved </p> <p>Follow‐up: at up to day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration to symptoms resolved was 12.00 days.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of symptoms resolved was 8.00 days (5.78 to 10.22 days).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −4.00</b> days </p> <p>(−6.22 to −1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids may decrease the duration to symptom resolution.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: during study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> <p>(0 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b> </p> <p>(0.09 to 2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1586</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>Very Low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of inhaled corticosteroids on serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: at up to day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> <p>(67 to 187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> </p> <p>(0.47 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids may result in little to no difference in adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infections</b> </p> <p>Follow‐up: during study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> <p>(10 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> </p> <p>(0.30 to 2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids may result in little to no difference in infections.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention group (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE working group grades evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimated from included studies (with 10% of participants being vaccinated at least once).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (very low number of events, wide CI).<br/><sup>c</sup>Downgraded one level for serious imprecision (low number of participants/events and optimal information size would be 3764 participants).<br/><sup>d</sup>Downgraded one level for serious risk of bias (partly measurement of the outcome affected by unblinded design, selection of the reported result, missing outcome data as the safety‐relevant outcome was not reported) and reporting bias (the safety‐relevant outcome was not reported).<br/><sup>e</sup>Downgraded one level for serious imprecision (low number of participants/events and wide CI). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015125-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015125-sec-0009"></div> <p>This work is part of a series of Cochrane Reviews investigating treatments and therapies for coronavirus disease 2019 (COVID‐19). Reviews in this series share information in the background section and methodology with the first published reviews about monoclonal antibodies (<a href="./references#CD015125-bbs2-0042" title="KreuzbergerN , HirschC , ChaiKL , PiechottaV , ValkSJ , EstcourtLJ , et al.SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 9. Art. No: CD013825. [DOI: 10.1002/14651858.CD013825.pub2]">Kreuzberger 2021</a>) and convalescent plasma (<a href="./references#CD015125-bbs2-0054" title="PiechottaV , IannizziC , ChaiKL , ValkSJ , KimberC , DorandoE , et al.Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub4]">Piechotta 2021</a>) from the German research project 'CEOsys' (COVID‐19 Evidence Ecosystem). </p> <section id="CD015125-sec-0010"> <h3 class="title" id="CD015125-sec-0010">Description of the condition</h3> <p>COVID‐19 is a rapidly spreading infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; <a href="./references#CD015125-bbs2-0073" title="World Health Organization.Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 16 July 2021).">WHO 2020a</a>). On 11 March 2020, the World Health Organization (WHO) declared the current COVID‐19 outbreak a pandemic. The severity of COVID‐19 is unprecedented in comparison to that of previous coronavirus outbreaks such as severe acute respiratory syndrome (SARS), which caused 813 deaths, and Middle East respiratory syndrome (MERS), which caused 858 deaths (<a href="./references#CD015125-bbs2-0071" title="World Health Organization.Cumulative number of reported probable cases of SARS. www.who.int/csr/sars/country/2003_07_11/en (accessed 1 July 2021).">WHO 2007</a>; <a href="./references#CD015125-bbs2-0072" title="World Health Organization.Middle East respiratory syndrome coronavirus (MERS-CoV). www.who.int/emergencies/mers-cov/en (accessed 16 July 2021).">WHO 2019</a>). Despite intensive international efforts to contain its spread, SARS‐CoV‐2 has resulted in a continuously rising number of cases and deaths with a clearly accelerating increase in the first months of 2021 (<a href="./references#CD015125-bbs2-0076" title="World Health Organization.WHO Coronavirus Disease (COVID-19) Dashboard. covid19.who.int (accessed 16 July 2021).">WHO 2021a</a>; <a href="./references#CD015125-bbs2-0077" title="World Health Organization.Weekly epidemiological update – 23 February 2021. www.who.int/publications/m/item/weekly-epidemiological-update---23-february-2021 (accessed 16 July 2021).">WHO 2021b</a>). In the meantime, the appearance of SARS‐CoV‐2 variants with higher transmissibility is further increasing infection rates (<a href="./references#CD015125-bbs2-0078" title="World Health Organization.SARS-CoV-2 variants. www.who.int/csr/don/31-december-2020-sars-cov2-variants/en (accessed 16 July 2021).">WHO 2021c</a>). </p> <p>The risk for a severe course of disease, hospitalisation, and mortality is higher among people aged 65 years or older; smokers; and those with certain underlying medical conditions such as cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), heart conditions, immunocompromised state, obesity, sickle cell disease, or type 2 diabetes mellitus (<a href="./references#CD015125-bbs2-0039" title="HuangC , WangY , LiX , RenL , ZhaoJ , HuY , et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020;395(10223):497-506.">Huang 2020</a>; <a href="./references#CD015125-bbs2-0045" title="LiangW , GuanW , ChenR , WangW , LiJ , XuK , et al.Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology2020;21(3):335-7.">Liang 2020</a>; <a href="./references#CD015125-bbs2-0073" title="World Health Organization.Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 16 July 2021).">WHO 2020a</a>; <a href="./references#CD015125-bbs2-0080" title="WilliamsonE , WalkerAJ , BhaskaranKJ , BaconS , BatesC , MortonCE , et al.Factors associated with COVID-19-related death using OpenSAFELY. Nature2020;584:430-6.">Williamson 2020</a>). COVID‐19 case fatality ratios vary widely between countries and reporting periods, from 0.0% to more than 25% (<a href="./references#CD015125-bbs2-0040" title="Johns Hopkins University.Mortality analyses. coronavirus.jhu.edu/data/mortality (accessed 16 July 2021).">Johns Hopkins University 2021</a>). However, these numbers may be misleading as they tend to overestimate the infection:fatality ratio due to varying testing frequency, a lack of reporting dates, and variations in case definitions, especially in the beginning of the pandemic when the main focus was on severe cases (<a href="./references#CD015125-bbs2-0074" title="World Health Organization.Estimating mortality from COVID-19 – scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1 (accessed 16 July 2021).">WHO 2020b</a>). </p> <p>The median incubation time is estimated to be five to six days, and 97.5% of symptomatic cases develop symptoms within 11.5 days of exposure (<a href="./references#CD015125-bbs2-0043" title="LauerSA , GrantzKH , BiQ , JonesFK , ZhengQ , MeredithHR , et al.The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine2020;172(9):577-82.">Lauer 2020</a>). Sore throat, cough, fever, headache, fatigue, and myalgia or arthralgia are the most commonly reported symptoms (<a href="./references#CD015125-bbs2-0065" title="StruyfT , DeeksJJ , DinnesJ , TakwoingiY , DavenportC , LeeflangMM , et al.Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013665. [DOI: 10.1002/14651858.CD013665]">Struyf 2020</a>). Other symptoms include dyspnoea, chills, nausea or vomiting, diarrhoea, and nasal congestion (<a href="./references#CD015125-bbs2-0073" title="World Health Organization.Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 16 July 2021).">WHO 2020a</a>). Most infected people (approximately 80%) have mild symptoms (<a href="./references#CD015125-bbs2-0081" title="WuZ , McGooganJM .Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42.">Wu 2020</a>), or remain completely asymptomatic (<a href="./references#CD015125-bbs2-0021" title="Buitrago-GarciaD , Egli-GanyD , CounotteMJ , HossmannS , ImeriH , Ipekci AzizM , et al.Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Medicine2020;17(9):e1003346.">Buitrago‐Garcia 2020</a>). A smaller proportion (approximately 14%) are affected by severe or critical disease which requires treatment at an intensive care unit (ICU) due to respiratory failure, septic shock, or multiple organ dysfunction (<a href="./references#CD015125-bbs2-0081" title="WuZ , McGooganJM .Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42.">Wu 2020</a>). In light of the extent of the COVID‐19 pandemic and the scarcity of effective treatments, there is an urgent need for effective therapies to save lives and to reduce the high burden on healthcare systems, especially in the face of evolving variants of the virus with the potential for increased transmissibility and the limited global availability of vaccines. </p> </section> <section id="CD015125-sec-0011"> <h3 class="title" id="CD015125-sec-0011">Description of the intervention</h3> <p>Corticosteroids are a group of stress hormones produced from the adrenal cortex. In addition to their stress‐mediated mechanisms for generating energy substrates, corticosteroids have anti‐inflammatory and immunosuppressive properties in higher doses and are applied widely in almost all medical fields (<a href="./references#CD015125-bbs2-0020" title="BarnesPJ .Corticosteroid effects on cell signalling. European Respiratory Journal2006;27(2):413-26. [DOI: 10.1183/09031936.06.00125404]">Barnes 2006</a>; <a href="./references#CD015125-bbs2-0057" title="RhenT , CidlowskiJA .Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. New England Journal of Medicine2005;353:1711-23. [DOI: 10.1056/NEJMra050541]">Rhen 2005</a>). The effects are based on the binding to intracellular receptors, which influences protein expression. In addition, glucocorticoids also develop extragenomic effects. All active ingredients are lipophilic and thus easily reach the cells via the cell membrane. Long‐term systemic corticosteroid therapy, unless in a very low dose, can be associated with many adverse effects (e.g. hypertension, osteoporosis, and diabetes). Inhaled corticosteroids have a lower risk of undesirable effects compared with systemic administration. They can be used as dose aerosols, inhalable powder, or inhalation capsules in different dosages (low, medium, and high dosages) depending on indication (<a href="./references#CD015125-bbs2-0024" title="Daley-YatesPT .Inhaled corticosteroids: potency, dose equivalence and therapeutic index. British Journal of Clinical Pharmacology2015;80(3):372-80. [DOI: doi:10.1111/bcp.12637]">Daley‐Yates 2015</a>). Inhaled corticosteroids reach the lower respiratory tract as a finely divided aerosol via the airflow and develop their effect directly on the bronchial mucosa. This form of administration is particularly important for the treatment of inflammatory respiratory diseases such as asthma or COPD (<a href="./references#CD015125-bbs2-0029" title="GeddesDM .Inhaled corticosteroids: benefits and risks. Thorax1992;47(6):404-7. [DOI: 10.1136/thx.47.6.404]">Geddes 1992</a>). However, many adverse effects are dose‐related and can include local effects such as oropharyngeal candidiasis, hoarseness, and increased risk of pneumonia, in addition to the systemic effects mentioned above (<a href="./references#CD015125-bbs2-0024" title="Daley-YatesPT .Inhaled corticosteroids: potency, dose equivalence and therapeutic index. British Journal of Clinical Pharmacology2015;80(3):372-80. [DOI: doi:10.1111/bcp.12637]">Daley‐Yates 2015</a>; <a href="./references#CD015125-bbs2-0055" title="PriceD , YawnB , BrusselleG , RossiA .Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Primary Care Respiratory Journal2012;22:92-100. [DOI: 10.4104/pcrj.2012.00092]">Price 2012</a>). </p> </section> <section id="CD015125-sec-0012"> <h3 class="title" id="CD015125-sec-0012">How the intervention might work</h3> <p>In COVID‐19, an imbalanced inflammation is thought to play a key role in the pathophysiology of hypoxaemic respiratory failure (<a href="./references#CD015125-bbs2-0059" title="Schulte-SchreppingJ , ReuschN , PaclikD , BaβlerK , SchlickeiserS , ZhangB , et al.Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell2020;182(6):1419-40. [DOI: 10.1016/j.cell.2020.08.001]">Schulte‐Schrepping 2020</a>). A systemic inflammatory response with an excessive release of cytokines and inflammatory mediators can lead to lung injury with the development of acute respiratory distress syndrome (ARDS). </p> <p>It has been proposed that corticosteroids could be clinically effective against severe and critical COVID‐19, due to their anti‐inflammatory and immunomodulatory properties (<a href="./references#CD015125-bbs2-0068" title="VillarJ , FerrandoC , MartínezD , AmbrósA , MuñozT , SolerJA , et al.Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respiratory Medicine2020;8(3):267-76. [DOI: 10.1016/S2213-2600(19)30417-5]">Villar 2020</a>). Furthermore, in vitro studies have shown that inhaled glucocorticoids have antiviral effectiveness due to two mechanisms: downregulation of the expression of <i>ACE2</i> and <i>TMPRSS2</i> genes, which are critical for viral cell entry (<a href="./references#CD015125-bbs2-0028" title="FinneyLJ , GlanvilleN , FarneH , AniscenkoJ , FenwickP , KempSV , et al.Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. Journal of Allergy and Clinical Immunology2021;147(2):510-9. [DOI: doi:10.1016/j.jaci.2020.09.034]">Finney 2021</a>; <a href="./references#CD015125-bbs2-0048" title="MatsuyamaS , NaoN , ShiratoK , KawaseM , SaitoS , TakayamaI , et al.Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proceedings of the National Academy of Sciences of the United States of America2020;117(13):7001-3. [DOI: 10.1073/pnas.2002589117]">Matsuyama 2020</a>; <a href="./references#CD015125-bbs2-0053" title="PetersMC , SajuthiS , DefordP , ChristensonS , RiosCL , MontgomeryMT , et al.COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. American Journal of Respiratory and Critical Care Medicine2020;202:83-90. [DOI: 10.1164/rccm.202003-0821OC]">Peters 2020</a>), and reduction of the replication of SARS‐CoV‐2 in airway epithelial cells (<a href="./references#CD015125-bbs2-0082" title="YamayaM , NishimuraH , DengX , SugawaraM , WatanabeO , NomuraK , et al.Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respiratory Investigation2020;58(3):155-68. [DOI: doi:10.1016/j.resinv.2019.12.005]">Yamaya 2020</a>). In addition, corticosteroids reduce the exacerbation rate in COPD and asthma, which is very often caused by viral infections (<a href="./references#CD015125-bbs2-0069" title="ViniolC , VogelmeierCF .Exacerbations of COPD. European Respiratory Review2018;27(147):1-9. [DOI: 10.1183/16000617.0103-2017]">Viniol 2018</a>). Observation from the early pandemic showed that people with bronchial asthma and COPD were less likely to be hospitalised for COVID‐19, which is postulated to be due to the routine medication with inhaled corticosteroids in those people (<a href="./references#CD015125-bbs2-0032" title="HalpinDM , FanerR , SibilaO , BadiaJR , AgustiA .Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?Lancet Respiratory Medicine2020;8(5):436-8. [DOI: 10.1016/S2213-2600(20)30167-]">Halpin 2020</a>). </p> </section> <section id="CD015125-sec-0013"> <h3 class="title" id="CD015125-sec-0013">Why it is important to do this review</h3> <p>Globally, the number of new COVID‐19 cases and deaths continue to increase with a substantial impact on healthcare systems. Vaccination remains a key component of options for response to address the ongoing circulation and reduce the impact of the dominant variants of concern. Despite the efforts to increase full vaccination uptake in people who are currently insufficiently vaccinated, some pharmaceutical interventions remain a mainstay in the management of COVID‐19. Treatment decisions should be informed by high‐quality, relevant, and up‐to‐date synthesised research evidence provided by international networks. There are several systematic reviews on the use of systemic corticosteroids for the treatment of COVID‐19 based on randomised controlled trials (RCTs) and non‐randomised studies (e.g. <a href="./references#CD015125-bbs2-0064" title="SterneJA .Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA2020;324(13):1330-41.">Sterne 2020</a>; <a href="./references#CD015125-bbs2-0067" title="vanPaassenJ , VosJS , HoekstraEM , NeumannKM , BootPC , ArbousSM .Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Critical Care2020;24(696):1-22.">van Paassen 2020</a>; <a href="./references#CD015125-bbs2-0070" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al.Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014963. [DOI: 10.1002/14651858.CD014963] [PMID: 34396514]">Wagner 2021a</a>). </p> <p>This systematic review fills current gaps by identifying, describing, evaluating, and meta‐analysing RCTs for inhaled corticosteroids on clinical outcomes as an additional treatment option in COVID‐19. We will search for RCTs on inhaled corticosteroids for COVID‐19 on a weekly basis and update this living systematic review once new relevant evidence becomes available to ensure the review remains current. For the most up‐to‐date information about the review, the results of the searches, and any new evidence being incorporated, readers are encouraged to check the update status information. The update status information will be updated whenever the searches are rerun. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015125-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015125-sec-0014"></div> <p>To assess whether inhaled corticosteroids are effective and safe in the treatment of COVID‐19; and to maintain the currency of the evidence, using a living systematic review approach. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015125-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015125-sec-0015"></div> <section id="CD015125-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015125-sec-0017"> <h4 class="title">Types of studies</h4> <p>The main description of methods is based on the standard template of the Cochrane Haematology review group and is in line with a series of Cochrane Reviews investigating treatments and therapies against COVID‐19. Specific adaptions related to the research question were made if necessary (see <a href="#CD015125-sec-0109">Differences between protocol and review</a>). The protocol for this review was registered with PROSPERO on 9 July 2021 (<a href="./references#CD015125-bbs2-0083" title="WagnerC , GrieselM , FichtnerF , SkoetzN , MikolajewskaA , StegemannM , et al.Efficacy and safety of inhaled corticosteroids for the treatment and prevention of SARS-CoV-2 infection (part of German Ecosystem Ceo-Sys). www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=266913 (accessed 22 February 2022). [PROSPERO: CRD42021266913]">Wagner 2021b</a>). </p> <p>To assess the efficacy and safety of inhaled corticosteroids against COVID‐19, we included RCTs, as this study design, if performed appropriately, provides the best evidence for experimental therapies in highly controlled therapeutic settings. We used the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015125-bbs2-0034" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from: training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). We would also have accepted cluster‐randomised trials for inclusion, if we had found any. We found no cross‐over studies, but would have excluded them because of the short duration of the disease and potential carry‐over effects of corticosteroids. </p> <p>We included the following formats, if sufficient information was available on study design, characteristics of participants, interventions, and outcomes: </p> <p> <ul id="CD015125-list-0001"> <li> <p>full‐text publications;</p> </li> <li> <p>preprint articles.</p> </li> </ul> </p> <p>We included preprints to have a complete overview of the ongoing research activity, especially for tracking newly emerging studies about systemic corticosteroids against COVID‐19. We did not apply any limitation with respect to the length of follow‐up. </p> </section> <section id="CD015125-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included people with a confirmed diagnosis of COVID‐19 and moderate‐to‐severe disease and people with a confirmed diagnosis of asymptomatic SARS‐CoV‐2 infection or mild COVID‐19 (as described in the study). We did not exclude any studies based on sex, ethnicity, disease severity, or setting. </p> </section> <section id="CD015125-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included the following intervention:</p> <p> <ul id="CD015125-list-0002"> <li> <p>any type or dose of inhaled corticosteroids.</p> </li> </ul> </p> <p>We included the following comparisons:</p> <p> <ul id="CD015125-list-0003"> <li> <p>inhaled corticosteroid plus standard care versus standard care (with or without placebo).</p> </li> </ul> </p> <p>Standard care in both arms had to be similar.</p> <p>We excluded the following interventions:</p> <p> <ul id="CD015125-list-0004"> <li> <p>topical corticosteroids.</p> </li> </ul> </p> </section> <section id="CD015125-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated core outcomes in accordance with the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for people with COVID‐19 (<a href="./references#CD015125-bbs2-0022" title="COMET.Core outcome set developers' response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 16 July 2021).">COMET 2020</a>; <a href="./references#CD015125-bbs2-0047" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al.A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>), and additional outcomes that have been prioritised by consumer representatives and the panel of the German "national treatment guidance for hospitalized COVID‐19 patients" (<a href="./references#CD015125-bbs2-0041" title="KlugeS , JanssensU , WelteT , Weber-CarstensS , SchälteG , Spinner CD et al.S3 Guideline – recommendations for inpatient therapy of patients with COVID-19 [S3-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19]. www.awmf.org/uploads/tx_szleitlinien/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2022-03.pdf (accessed 7 March 2022); ( ): .">Kluge 2022</a>). </p> <p>We defined this outcome set for hospitalised people with a confirmed diagnosis of COVID‐19 and moderate‐to‐severe disease, according to WHO clinical progression scale stage 4 to 9 (<a href="./references#CD015125-bbs2-0047" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al.A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>) (i.e. all patients who were hospitalised because of symptomatic COVID‐19 treated with all different levels of respiratory support, such as no additional oxygen, low‐flow oxygen prongs or mask ('low‐flow oxygen'), high‐flow oxygen or non‐invasive ventilation, invasive mechanical ventilation inclusively extracorporeal membrane oxygenation) and people with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease, according to the WHO clinical progression scale (<a href="./references#CD015125-bbs2-0047" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al.A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>). Of note, the reader will encounter respiratory support both as baseline characteristic and as outcome measure – in the latter case changes in the level of support will be utilised. </p> <p>In review updates, we will also evaluate patient‐reported experience measures (PREMS), as suggested by the consumer editor. However, up to October 2021, the included studies did not report PREMS. </p> <section id="CD015125-sec-0021"> <h5 class="title">People with a confirmed diagnosis of COVID‐19: moderate or severe disease</h5> <section id="CD015125-sec-0022"> <h6 class="title">Efficacy of inhaled corticosteroids</h6> <section id="CD015125-sec-0023"> <p><b>Prioritised outcomes (included in the summary of findings table)</b></p> <p> <ul id="CD015125-list-0005"> <li> <p>All‐cause mortality at day 30, day 60, time‐to‐event, and up to longest follow‐up.</p> </li> <li> <p>Clinical status at day 30, day 60, and up to longest follow‐up, including:</p> <ul id="CD015125-list-0006"> <li> <p>worsening of clinical status:</p> <ul id="CD015125-list-0007"> <li> <p>participants with clinical deterioration (new need for invasive mechanical ventilation) or death; </p> </li> </ul> </li> <li> <p>improvement of clinical status:</p> <ul id="CD015125-list-0008"> <li> <p>participants discharged alive. Participants should be discharged without clinical deterioration or death. </p> </li> </ul> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to seven days; up to 30 days, and longest follow‐up available. </p> </li> </ul> </p> </section> </section> <section id="CD015125-sec-0024"> <h6 class="title">Safety of inhaled corticosteroids</h6> <p> <ul id="CD015125-list-0009"> <li> <p>Serious adverse events during the study period, defined as number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events)). </p> </li> <li> <p>Adverse events (any grade) during the study period, defined as number of participants with any adverse event. </p> </li> <li> <p>Hospital‐acquired infections during the study period.</p> </li> </ul> </p> </section> </section> <section id="CD015125-sec-0025"> <h5 class="title">People with a confirmed diagnosis of asymptomatic SARS‐CoV‐2 infection or mild COVID‐19</h5> <section id="CD015125-sec-0026"> <h6 class="title">Efficacy of inhaled corticosteroids</h6> <section id="CD015125-sec-0027"> <p><b>Prioritised outcomes (included in the summary of findings table)</b></p> <p> <ul id="CD015125-list-0010"> <li> <p>All‐cause mortality at day 30, day 60, time‐to‐event, and up to longest follow‐up.</p> </li> <li> <p>Admission to hospital or death within 30 days.</p> </li> <li> <p>Symptom resolution:</p> <ul id="CD015125-list-0011"> <li> <p>all initial symptoms resolved (asymptomatic) at day 14;</p> </li> <li> <p>duration to symptom resolution.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD015125-sec-0028"> <p><b>Prioritised outcomes (not included in the summary of findings table)</b></p> <p> <ul id="CD015125-list-0012"> <li> <p>Symptom resolution:</p> <ul id="CD015125-list-0013"> <li> <p>all initial symptoms resolved (asymptomatic) at day 30.</p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to seven days, up to 30 days, and longest follow‐up available. </p> </li> </ul> </p> </section> </section> <section id="CD015125-sec-0029"> <h6 class="title">Safety of inhaled corticosteroids</h6> <p> <ul id="CD015125-list-0014"> <li> <p>Serious adverse events during the study period, defined as number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events)). </p> </li> <li> <p>Adverse events (any grade) during the study period, defined as number of participants with any adverse event. </p> </li> <li> <p>Infections during the study period.</p> </li> <li> <p>PREMs (e.g. through questionnaires, including information on satisfaction with the treatment to investigate possible reasons for deviations from intended interventions). </p> </li> </ul> </p> </section> <section id="CD015125-sec-0030"> <h6 class="title">Timing of outcome measurement</h6> <p>In case of time‐to‐event analysis (e.g. for time to clinical improvement), we included the outcome measure based on the longest follow‐up time. We also collected information on outcomes from all other time points reported in the publications. </p> </section> </section> </section> </section> <section id="CD015125-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD015125-sec-0032"> <h4 class="title">Electronic searches</h4> <p>Our information specialist (MIM) conducted systematic searches in the following sources from the inception of each database to 7 October 2021 (search date for all databases) and placed no restrictions on the language of publication. </p> <p> <ul id="CD015125-list-0015"> <li> <p>Cochrane COVID‐19 Study Register (CCSR) (<a href="https://www.covid-19.cochrane.org" target="_blank">www.covid-19.cochrane.org</a>), comprising: </p> <ul id="CD015125-list-0016"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), monthly updates;</p> </li> <li> <p>MEDLINE (PubMed), daily updates;</p> </li> <li> <p>Embase.com, weekly updates;</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), daily updates; </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch</a>), weekly updates; </p> </li> <li> <p>medRxiv (<a href="https://www.medrxiv.org" target="_blank">www.medrxiv.org</a>), weekly updates. </p> </li> </ul> </li> <li> <p>Web of Science Core Collection (Clarivate), from 1 January 2020 onwards:</p> <ul id="CD015125-list-0017"> <li> <p>Science Citation Index Expanded (from 1945);</p> </li> <li> <p>Emerging Sources Citation Index (from 2015).</p> </li> </ul> </li> <li> <p>WHO COVID‐19 Global literature on coronavirus disease (<a href="https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/" target="_blank">search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/</a>). </p> </li> </ul> </p> <p>Database search results for Web of Science were restricted to publications from 2020 to October 2021, as no treatment trials on COVID‐19 were registered prior to January 2020. For detailed search strategies, see <a href="./appendices#CD015125-sec-0101">Appendix 1</a>. </p> <p>We did not conduct separate searches of the databases required by the MECIR standards (<a href="./references#CD015125-bbs2-0035" title="HigginsJP , LassersonT , ChandlerJ , ToveyD , ThomasJ , FlemyngE , et al.Methodological expectations of Cochrane intervention reviews. www.community.cochrane.org/mecir-manual/ (accessed 3 August 2021).">Higgins 2021a</a>), since these databases are already regularly searched for the production of the CCSR. </p> <section id="CD015125-sec-0033"> <h5 class="title">Living systematic review considerations</h5> <p>We will use the CCSR to monitor newly published results of RCTs on inhaled corticosteroids on a weekly basis. </p> </section> </section> <section id="CD015125-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We identified other potentially eligible studies or ancillary publications by searching the reference lists of included studies and systematic reviews. </p> <section id="CD015125-sec-0035"> <h5 class="title">Living systematic review considerations</h5> <p>The signal for updating this review will stem from the weekly monitoring of the published relevant RCTs via the CCSR, as described under <a href="#CD015125-sec-0032">Electronic searches</a>. Once the decision to update the review has been made, the methods mentioned in this section will be incorporated in the review update. </p> </section> </section> </section> <section id="CD015125-sec-0036"> <h3 class="title" id="CD015125-sec-0036">Data collection and analysis</h3> <section id="CD015125-sec-0037"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CW, AF) independently screened the results of the search for eligibility by reading the titles and abstracts using EndNote Software (<a href="./references#CD015125-bbs2-0027" title="EndNote X9.Clarivate, 2020.">EndNote X9</a>). We coded the abstracts as either 'include' or 'exclude'. In the case of disagreement or if it was unclear whether we should retrieve the abstract, we obtained the full‐text publication for further discussion. Two review authors assessed the full‐text articles of selected studies. If the two review authors were unable to reach a consensus, they consulted the third review author to reach a final decision. </p> <p>We documented the study selection process in a PRISMA flow chart (<a href="./references#CD015125-bbs2-0050" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG .Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>), and showed the total numbers of retrieved references and the numbers of included and excluded studies. We listed all studies that we excluded after full‐text assessment and the reasons for their exclusion in the <a href="./references#CD015125-sec-0117" title="">Characteristics of excluded studies</a> section. </p> </section> <section id="CD015125-sec-0038"> <h4 class="title">Data extraction and management</h4> <p>We conducted data extraction according to Cochrane guidelines (<a href="./references#CD015125-bbs2-0044" title="LiT , HigginsJP , DeeksJJ .Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Li 2020</a>). Two of four review authors (MG, CW, AF, AM) extracted data independently and in duplicate, using a customised data extraction form developed in Microsoft Excel (<a href="./references#CD015125-bbs2-0049" title="Microsoft Excel.Microsoft Corporation. Microsoft Corporation, 2018. office.microsoft.com/excel.">Microsoft Excel</a>). We solved disagreements by discussion. If no agreement was obtained, a third review author was involved to solve the disagreement. </p> <p>Two of three review authors (MG, CW, AF) independently assessed eligible studies obtained in the process of study selection (as described above) for methodological quality and risk of bias. If the review authors were unable to reach a consensus, a third review author was consulted. </p> <p>We extracted the following information if reported.</p> <p> <ul id="CD015125-list-0018"> <li> <p>General information: author, title, source, publication date, country, language, duplicate publications. </p> </li> <li> <p>Study characteristics: trial design, setting and dates, source of participants, inclusion/exclusion criteria, comparability of groups, treatment cross‐overs, compliance with assigned treatment, length of follow‐up. </p> </li> <li> <p>Participant characteristics: age, sex, ethnicity, number of participants recruited/allocated/evaluated, number of participants with positive, negative, or unknown polymerase chain reaction (PCR) test result, additional diagnoses, severity of disease, previous treatments, concurrent treatments, comorbidities (e.g. diabetes, immunosuppression). </p> </li> <li> <p>Interventions: type of corticosteroid, dose, frequency, timing, duration and route of administration, setting (e.g. hospitalised, non‐hospitalised), duration of follow‐up. </p> </li> <li> <p>Control interventions: placebo, no treatment, or other intervention; dose, frequency, timing, duration, and route of administration; setting; duration of follow‐up. </p> </li> <li> <p>Outcomes: as specified under <a href="#CD015125-sec-0020">Types of outcome measures</a>. </p> </li> <li> <p>Risk of bias assessment: randomisation process, deviations from the intended interventions, missing outcome data, measurement of the outcome, selection of the reported result. </p> </li> </ul> </p> </section> <section id="CD015125-sec-0039"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Risk of Bias 2 (RoB 2) tool (version of 22 August 2019) to analyse the risk of bias of study results (<a href="./references#CD015125-bbs2-0063" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweN , BoutronI , et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). Of interest for this review was the effect of the assignment to the intervention (the intention‐to‐treat (ITT) effect), thus, we performed all assessments with RoB 2 on this effect. The outcomes that we assessed were those specified for inclusion in the summary of findings table. </p> <p>Two of five review authors (MG, CW, AF, JD, AN) independently assessed the risk of bias for each outcome. In case of discrepancies among their judgements and inability to reach consensus, we consulted another review author to reach a final decision. We assessed the following types of bias for RCTs as outlined in Chapter 8 (<a href="./references#CD015125-bbs2-0036" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA .Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021b</a>) and for cluster‐RCTs as outlined in Chapter 23 (Table 23.1.a; <a href="./references#CD015125-bbs2-0037" title="HigginsJ , EldridgeS , LiT .Chapter 23: Including variants on randomised trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021c</a>) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> <p>For RCTs:</p> <p> <ul id="CD015125-list-0019"> <li> <p>bias arising from the randomisation process;</p> </li> <li> <p>bias due to deviations from the intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome;</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>For cluster‐RCTs:</p> <p> <ul id="CD015125-list-0020"> <li> <p>bias arising from the randomisation process;</p> </li> <li> <p>bias arising from the timing of identification and recruitment of participants;</p> </li> <li> <p>bias due to deviations from intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome;</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>To address these types of bias we used the signalling questions recommended in RoB 2 and made a judgement using the following options. </p> <p> <ul id="CD015125-list-0021"> <li> <p>'Yes': if there was firm evidence that the question was fulfilled in the study (i.e. the study was at low or high risk of bias for the given the direction of the question). </p> </li> <li> <p>'Probably yes': a judgement was made that the question was fulfilled in the study (i.e. the study was at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No': if there was firm evidence that the question was unfilled in the study (i.e. the study was at low or high risk of bias for the given the direction of the question). </p> </li> <li> <p>'Probably no': a judgement was made that the question was unfilled in the study (i.e. the study was at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No information': if the study report did not provide sufficient information to allow any judgement. </p> </li> </ul> </p> <p>We used the algorithms proposed by RoB 2 to assign each domain one of the following levels of bias. </p> <p> <ul id="CD015125-list-0022"> <li> <p>Low risk of bias.</p> </li> <li> <p>Some concerns.</p> </li> <li> <p>High risk of bias.</p> </li> </ul> </p> <p>Subsequently, we derived an overall risk of bias rating for each prespecified outcome in each study in accordance with the following suggestions. </p> <p> <ul id="CD015125-list-0023"> <li> <p>'Low risk of bias': we judged the trial at low risk of bias for all domains for this result. </p> </li> <li> <p>'Some concerns': we judged the trial to raise some concerns in at least one domain for this result, but not at high risk of bias for any domain. </p> </li> <li> <p>'High risk of bias': we judged the trial at high risk of bias in at least one domain for the result, or we judged the trial to have some concerns for multiple domains in a way that substantially lowered confidence in the results. </p> </li> </ul> </p> <p>We used the RoB 2 Excel tool to implement RoB 2 (available on the <a href="https://www.riskofbias.info/" target="_blank">riskofbias.info</a> website), stored, and presented our detailed RoB 2 assessments in the analyses section and as supplementary online material. </p> </section> <section id="CD015125-sec-0040"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous outcomes, we recorded the mean, standard deviation (SD), and total number of participants in both treatment and control groups. Where continuous outcomes used the same scale, we performed analyses using the mean difference (MD) with 95% confidence intervals (CI). For continuous outcomes measured with different scales, we planned to perform analyses using the standardised mean difference (SMD), but this was not needed in this review. For interpreting SMDs, we planned to re‐express SMDs in the original units of a particular scale with the most clinical relevance and impact (e.g. clinical symptoms with the WHO Clinical Progression Scale (<a href="./references#CD015125-bbs2-0075" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection.A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020c</a>)). </p> <p>For dichotomous outcomes, we recorded the number of events and total number of participants in both treatment and control groups. We reported the pooled risk ratio (RR) with a 95% CI (<a href="./references#CD015125-bbs2-0025" title="DeeksJJ , HigginsJP , AltmanDG .Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). </p> <p>We planned to extract and report hazard ratios (HRs) for time‐to‐event outcomes (e.g. time to recovery), but there were no data available. There was also no need to estimate the HR as accurately as possible from available data using the methods proposed by Parmar and Tierney (<a href="./references#CD015125-bbs2-0052" title="ParmarMK , TorriV , StewartL .Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>; <a href="./references#CD015125-bbs2-0066" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR .Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>). </p> <p>We received the advice from a statistician to not use Peto odds ratio instead of RR when event rates were low, since we only have a few studies in our main analysis. </p> </section> <section id="CD015125-sec-0041"> <h4 class="title">Unit of analysis issues</h4> <p>The aim of this review was to summarise trials that analysed data at the level of the participant. We collated multiple reports of one study so that the study, and not the report, was the unit of analysis. </p> <section id="CD015125-sec-0042"> <h5 class="title">Studies with multiple treatment groups</h5> <p>As recommended in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015125-bbs2-0038" title="HigginsJP , LiT , DeeksJJ .Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021d</a>), for studies with multiple treatment groups of the same intervention (i.e. dose, route of administration), we planned to evaluate whether study arms were sufficiently homogeneous to be combined. If arms could not be pooled, we planned to compare each arm with the common comparator separately. For pair‐wise meta‐analysis, we planned to split the 'shared' group into two or more groups with smaller sample size, and include two or more (reasonably independent) comparisons. For this purpose, for dichotomous outcomes, we planned to divide both the number of events and the total number of participants, and for continuous outcomes, we planned to divide the total number of participants with unchanged means and SDs. </p> </section> </section> <section id="CD015125-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>Missing data can occur on different levels (<a href="./references#CD015125-bbs2-0025" title="DeeksJJ , HigginsJP , AltmanDG .Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). </p> <p> <ul id="CD015125-list-0024"> <li> <p>Missing studies: our comprehensive search for RCTs including registry entries aimed at providing an overview on all published, ongoing, and planned studies. We included too few studies to assess publication bias by a funnel plot. </p> </li> <li> <p>Missing outcomes: if an outcome of interest to us was prespecified but not reported we considered that in the GRADE process and comment in the Discussion section. </p> </li> <li> <p>Missing summary data: if missing summary data of an outcome of interest necessary for meta‐analysis were missing, we contacted the authors. </p> </li> <li> <p>Missing participants: whenever possible, we contacted the original investigators to request missing data. We assumed data to be missing at random when the rate of missingness across arms was comparable and the characteristics of participants with missing data were comparable to the characteristics of participants without missing data. Otherwise, we assumed data not to be missing at random. For the primary analysis, we conducted a complete‐case analysis by excluding participants with missing outcome data from the meta‐analysis. </p> </li> <li> <p>We performed sensitivity analyses to assess how robust results were to a worst‐case scenario assumption. </p> </li> <li> <p>We addressed the potential impact of missing data under <a href="#CD015125-sec-0093">Potential biases in the review process</a>. </p> </li> <li> <p>Missing study‐level characteristics: outcomes were not available stratified by potentially important characteristics such as sex, age, or ethnicity. </p> </li> </ul> </p> <p>We requested data for all outcomes for one study because the trial reported it partly for participants who received inhaled corticosteroids plus hydroxychloroquine (<a href="./references#CD015125-bbs2-0009" title="SongJY , YoonJG , SeoYB , LeeJ , EomJS , LeeJS , et al.Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomised, open-label, phase 2 trial. Journal of Clinical Medicine2021;10(16):3545. [DOI: 10.3390/jcm10163545]">Song 2021</a>). Furthermore, we asked the authors to specify the setting of their study, as it was unclear from the publication whether the participants were hospitalised and hence what their disease severity was at baseline. </p> </section> <section id="CD015125-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic (<a href="./references#CD015125-bbs2-0033" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG .Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), and visual examination, to assess possible heterogeneity (I² &gt; 30% to signify moderate heterogeneity, I² &gt; 75% to signify considerable heterogeneity; <a href="./references#CD015125-bbs2-0025" title="DeeksJJ , HigginsJP , AltmanDG .Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). If heterogeneity was above 80%, we planned to explore potential causes through sensitivity and subgroup analyses. If we could not find a reason for heterogeneity, we did not perform a meta‐analysis but planned to comment on results from all studies and present these in tables. </p> <p>As the heterogeneity was never above 80%, we did not explore potential causes through sensitivity and subgroup analyses. However, we will do this for future updates. </p> </section> <section id="CD015125-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We searched trials registries to identify completed trials that had not been published elsewhere, to minimise or determine publication bias. We intended to explore potential publication bias by generating a funnel plot and statistically testing this by conducting a linear regression test for meta‐analyses involving at least 10 trials (<a href="./references#CD015125-bbs2-0063" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweN , BoutronI , et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). We would have considered P &lt; 0.1 as significant for this test. </p> <p>We planned to generate a funnel plot, but had fewer than 10 studies. We will produce a funnel plot for future updates. </p> </section> <section id="CD015125-sec-0046"> <h4 class="title">Data synthesis</h4> <p>If the clinical and methodological characteristics of individual studies were sufficiently homogeneous, we pooled the data in a meta‐analysis. We performed analyses according to the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015125-bbs2-0025" title="DeeksJJ , HigginsJP , AltmanDG .Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). We analysed trials including different severities of disease separately grouping them with respect to disease severity according to need for respiratory support at randomisation (see <a href="#CD015125-sec-0020">Types of outcome measures</a>). We treated placebo and standard care as the same intervention, as well as standard care at different institutions and time points. For the primary analyses, data were pooled regardless of risk of bias. </p> <p>We used Review Manager Web software for analyses (<a href="./references#CD015125-bbs2-0056" title="Review Manager Web (RevMan Web).The Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web 2019</a>). One review author entered the data into the software, and a second review author checked the data for accuracy. We used the random‐effects model for all analyses as we anticipated that true effects were related, but were not the same for included studies. If we deemed meta‐analysis inappropriate for a certain outcome because of heterogeneity of included studies both statistically or conceptually or for too high risk of bias, we presented descriptive statistics only. </p> <p>If meta‐analysis was possible, we assessed the effects of potential biases in sensitivity analyses (see <a href="#CD015125-sec-0048">Sensitivity analysis</a>). For binary outcomes, we based the estimation of the between‐study variance using the Mantel‐Haenszel method. We planned to explore heterogeneity above 80% with subgroup analyses. If we could not find a cause for the heterogeneity, we did not perform a meta‐analysis, but commented on the results as a narrative with the results from all studies presented in tables. </p> </section> <section id="CD015125-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Because of clinical relevance, we planned subgroup analyses of mortality for the following characteristics. </p> <p> <ul id="CD015125-list-0025"> <li> <p>Sociodemographic characteristics (e.g. sex, age, ethnicity).</p> </li> <li> <p>Comorbidities.</p> </li> <li> <p>Different dosage.</p> </li> <li> <p>Different timing.</p> </li> <li> <p>Vaccination status.</p> </li> </ul> </p> <p>Due to insufficient data, we were unable to perform these subgroup analyses.</p> </section> <section id="CD015125-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analysis of mortality for the following potential confounders.</p> <p> <ul id="CD015125-list-0026"> <li> <p>Risk of bias assessment components (studies with a low risk of bias or some concerns versus studies with a high risk of bias). </p> </li> <li> <p>High rate of missing data.</p> </li> </ul> </p> <p>Because there were no studies with a high risk of bias or high rate of missing data that reported mortality, we could not perform a sensitivity analysis. </p> <p>We performed sensitivity analysis for mortality for the following potential confounders.</p> <p> <ul id="CD015125-list-0027"> <li> <p>Fixed‐effect versus random‐effects model.</p> </li> <li> <p>Preprint versus journal publication.</p> </li> </ul> </p> </section> <section id="CD015125-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the certainty of the evidence for the following outcomes, and prepared one summary of findings table per population. </p> <section id="CD015125-sec-0050"> <h5 class="title">Summary of findings</h5> <p>We used <a href="./references#CD015125-bbs2-0031" title="GRADEpro GDT.Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT </a>software to create summary of findings tables. For time‐to‐event outcomes, we planned to calculate absolute effects at specific time points, as recommended in the GRADE guidance (<a href="./references#CD015125-bbs2-0062" title="SkoetzN , GoldkuhleM , vanDalenEC , AklEA , TrivellaM , MustafaRA , et al.GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles. Journal of Clinical Epidemiology2020;118:124-31.">Skoetz 2020</a>). </p> <p>According to Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, the "most critical and/or important health outcomes, both desirable and undesirable, limited to seven or fewer outcomes" should be included in the summary of findings tables (<a href="./references#CD015125-bbs2-0060" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al.Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Schünemann 2020</a>). We included outcomes prioritised according to the core outcome sets for studies for the treatment of people with confirmed COVID‐19 (<a href="./references#CD015125-bbs2-0022" title="COMET.Core outcome set developers' response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 16 July 2021).">COMET 2020</a>), and patient relevance. We included the following outcomes. </p> <section id="CD015125-sec-0051"> <h6 class="title">People with a confirmed diagnosis of COVID‐19: moderate or severe disease</h6> <p> <ul id="CD015125-list-0028"> <li> <p>All‐cause mortality at day 30, day 60, time‐to‐event, and at hospital discharge.</p> </li> <li> <p>Clinical status at day 30, day 60, and up to longest follow‐up, including:</p> <ul id="CD015125-list-0029"> <li> <p>worsening of clinical status:</p> <ul id="CD015125-list-0030"> <li> <p>participants with clinical deterioration (new need for invasive mechanical ventilation) or death; </p> </li> </ul> </li> <li> <p>improvement of clinical status:</p> <ul id="CD015125-list-0031"> <li> <p>participants discharged alive. Participants should be discharged without clinical deterioration or death. </p> </li> </ul> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to 7 days; up to 30 days, and longest follow‐up available. </p> </li> <li> <p>Serious adverse events during the study period, defined as number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events)). </p> </li> <li> <p>Adverse events (any grade) during the study period, defined as number of participants with any adverse event. </p> </li> <li> <p>Hospital‐acquired infections during the study period.</p> </li> </ul> </p> </section> <section id="CD015125-sec-0052"> <h6 class="title">People with a confirmed diagnosis of asymptomatic SARS‐CoV‐2 infection or mild COVID‐19</h6> <p> <ul id="CD015125-list-0032"> <li> <p>All‐cause mortality at day 30, day 60, time‐to‐event, and up to longest follow‐up.</p> </li> <li> <p>Admission to hospital or death within 30 days.</p> </li> <li> <p>Symptom resolution:</p> <ul id="CD015125-list-0033"> <li> <p>all initial symptoms resolved (asymptomatic) at day 14;</p> </li> <li> <p>duration to symptom resolution.</p> </li> </ul> </li> <li> <p>Serious adverse events during the study period, defined as number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events)). </p> </li> <li> <p>Adverse events (any grade) during the study period, defined as number of participants with any adverse event. </p> </li> <li> <p>Infections during the study period.</p> </li> </ul> </p> </section> </section> <section id="CD015125-sec-0053"> <h5 class="title">Assessment of the certainty of the evidence</h5> <p>We used the GRADE approach to assess the certainty in the evidence for the above outcomes.</p> <p>The GRADE approach uses five domains (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty in the body of evidence for each prioritised outcome. </p> <p>We downgraded our certainty of evidence for:</p> <p> <ul id="CD015125-list-0034"> <li> <p>serious (−1) or very serious (−2) risk of bias;</p> </li> <li> <p>serious (−1) or very serious (−2) inconsistency;</p> </li> <li> <p>serious (−1) or very serious (−2) uncertainty about directness;</p> </li> <li> <p>serious (−1) or very serious (−2) imprecise or sparse data;</p> </li> <li> <p>serious (−1) or very serious (−2) probability of reporting bias.</p> </li> </ul> </p> <p>The GRADE system used the following criteria for assigning grade of evidence.</p> <p> <ul id="CD015125-list-0035"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We followed the current GRADE guidance for these assessments in its entirety as recommended in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015125-bbs2-0060" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al.Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Schünemann 2020</a>). </p> <p>We used the overall risk of bias judgement, derived from the RoB 2 Excel tool, to inform our decision on downgrading for risk of bias. We phrased the findings and certainty in the evidence as suggested in the informative statement guidance (<a href="./references#CD015125-bbs2-0058" title="SantessoN , GlentonC , DahmP , GarnerP , AklA , AlperB , et al.GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35.">Santesso 2020</a>). </p> </section> <section id="CD015125-sec-0054"> <h5 class="title">Methods for future updates</h5> <section id="CD015125-sec-0055"> <h6 class="title">Living systematic review considerations</h6> <p>Our information specialist (MIM) will provide us with new search records each month, which two review authors will screen, evaluate, extract, and integrate following the guidance for Cochrane living systematic reviews (<a href="./references#CD015125-bbs2-0046" title="Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode (Version December 2019). Available at community.cochrane.org/review-production/production-resources/living-systematic-reviews (accessed 16 July 2021).">Living Evidence Network 2019</a>). </p> <p>We will manually check platform trials that were previously identified and listed as 'studies awaiting classification' for additional treatment arms. </p> <p>We will wait until the accumulating evidence changes our conclusions of the implications of research and practice before republishing the review. We will consider one or more of the following components to inform this decision. </p> <p> <ul id="CD015125-list-0036"> <li> <p>The findings of one or more prioritised outcomes for population with virologically confirmed SARS‐CoV‐2 infection. </p> </li> <li> <p>The credibility (e.g. GRADE rating) of one or more prioritised outcomes.</p> </li> <li> <p>New settings, populations, interventions, comparisons, or outcomes studied.</p> </li> </ul> </p> <p>In case of emerging policy relevance because of global controversies around the intervention, we will consider republishing an updated review even though our conclusions remain unchanged. We will review the review scope and methods approximately monthly, or more frequently if appropriate, in light of potential changes in COVID‐19 research (e.g. when additional comparisons, interventions, subgroups, or outcomes, or new review methods become available). </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015125-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015125-sec-0056"></div> <section id="CD015125-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD015125-sec-0058"> <h4 class="title">Results of the search</h4> <p>We searched all databases and screened the resulting records up to 7 October 2021. We identified 1560 records. After removing duplicates, we screened 1329 records based on their titles and abstracts. We excluded 1305 records that did not meet the inclusion criteria. Of the remaining 24 records, we included 23 records: </p> <p> <ul id="CD015125-list-0037"> <li> <p>three RCTs (in six records) for inclusion in this review;</p> </li> <li> <p>five RCTs (in six records) are awaiting classification;</p> </li> <li> <p>10 RCTs (in 11 records) are ongoing.</p> </li> </ul> </p> <p>The study flow diagram in <a href="#CD015125-fig-0001">Figure 1</a> illustrates the study selection process according to PRISMA guidelines (<a href="./references#CD015125-bbs2-0050" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG .Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>). </p> <div class="figure" id="CD015125-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD015125-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD015125-sec-0059"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD015125-sec-0116" title="">Characteristics of included studies</a> table and <a href="#CD015125-tbl-0002">Table 1</a>. </p> <div class="table" id="CD015125-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies for the comparison: inhaled corticosteroid plus standard care versus standard care (with or without placebo)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to steroids and analysed in this review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to control and analysed in this review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity at randomisation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide 160 μg per actuation, 2 actuations twice daily (total daily dose 640 μg) + standard care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants had an oxygen saturation of ≥ 93% on room air; had ≥ 1 of the following symptoms of COVID‐19: fever, cough, or dyspnoea </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide, 400 µg per actuation (2 puffs twice daily; total dose 1600 µg) + standard care (antipyretics and honey) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With symptoms of COVID‐19 (new‐onset cough and fever or anosmia, or both) within 7 days </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide 800 µg twice daily + standard care for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>787 (analysed concurrent and SARS‐CoV‐2‐positive population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>838 (analysed concurrent andSARS‐CoV‐2‐positive population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, platform trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing symptoms of confirmed or suspected COVID‐19 (high temperature or new, continuous cough or change in sense of smell/taste, or a combination of these) within 14 days </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RCT: randomised controlled trial; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2. </p> </div> </div> <section id="CD015125-sec-0060"> <h5 class="title">Designs of the studies and publication status</h5> <p>None of the studies were cluster‐RCTs. We included three RCTs with 3607 participants, of whom 1343 were allocated to inhaled corticosteroids plus standard care and 2264 to standard care (with or without placebo). One open‐label, parallel‐group, phase 2 clinical trial allocated 146 participants of whom eight (6%) were PCR‐negative at randomisation (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>); one open‐label, multi‐arm, adaptive platform RCT allocated 3061 participants to inhaled corticosteroids plus standard care or standard care (<a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>); one double‐blind placebo‐controlled trial allocated 400 participants eligible for inclusion if they had a positive SARS‐CoV‐2 molecular or antigen diagnostic sample (no information on percentage of PCR‐positive participants) (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>). </p> <p>From the allocated 3061 participants in <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, we used data from 1625 in this review. We restricted the analysis to participants who were randomised concurrently and were confirmed as SARS‐CoV‐2 positive. This was to reduce the risk of bias and indirectness arising from analysis of outcomes in participants included only on the basis of symptoms or who were randomised to usual care prior to the addition of budesonide. Comparing study participants recruited under different editions of the trial protocol, were treated according to changes in therapy or prophylaxis (e.g. vaccination) over time or were recruited in the context of other local regulations during the pandemic (e.g. contact restrictions, lockdown) and diagnostic options (e.g. access to PCR testing) would limit the applicability of evidence from this study. </p> <p>The number of participants included in the analyses in this review was 2171. The number of participants analysed for the respective endpoints ranged between 139 and 2132 depending on the availability of data. </p> <p>The three studies were performed as remote pragmatic outpatient trials partly relying on electronic self‐assessments and telephone calls. <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> was performed in one centre in the community in Oxfordshire, UK, while two studies were multicentric: <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> with multisite and multimethods enrolment in the UK and <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> in 10 centres in the US. All three included studies were performed in high‐income countries. However, the investigators of <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> undertook extensive community outreach to increase recruitment from ethnic minority and socially deprived communities. </p> <p>All studies reported information on the responsible ethics committee and the financial support. <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> and <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> were funded by departmental or governmental resources as well as non‐profit organisations: the National Institute for Health Research (NIHR) Biomedical Research Centre (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>) and NIHR and United Kingdom Research Innovation (<a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). Both studies also received support by AstraZeneca producing the intervention medication (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, including individual authors). <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> was funded by Covis Pharma GmbH producing the intervention medication. </p> <p>Two trials were peer‐reviewed publications in indexed journals (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>); one study was available as a preprint at the time of the publication of this review (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>). All included studies registered a study protocol prospectively. </p> </section> <section id="CD015125-sec-0061"> <h5 class="title">Participants</h5> <p>All three studies recruited participants in the outpatient setting: in participating general medical practices (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>), via local COVID‐19 testing sites (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>), as well online or by telephone (<a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>), and public and private academic and non‐academic centres (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>). Positive PCR rates among the participants differed significantly across the studies. In <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, the virological confirmation of the SARS‐CoV‐2 infection (through PCR or rapid antigen test) was not mandatory to participate in the study and only 87% of all participants randomly assigned to budesonide, usual care alone, or other treatments were PCR tested. About 67% of those PCR‐tested participants and 82.2% of those concurrently randomised in the budesonide or usual care arms had a positive PCR‐test result. In this review, we analysed only PCR‐positive participants from the study <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> (SARS‐CoV‐2‐positive concurrent randomisation analysis population) to reduce risk of bias and indirectness. There is no information on how many participants who carried out a rapid antigen test. In <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>, the rate of positive PCR tests was not reported. However, all participants had a positive PCR or an antigen test, since it was the inclusion criterion of the study, and therefore could be defined as confirmed virologically. In <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>, 94% of participants were PCR‐positive. </p> <p>In two studies all participants were adults (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). In <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>, the participants had to be at least 12 years of age. In this study, the mean age of all participants was 43.3 (SD 16.89) years, 4% of all participants were aged less than 18 years. In <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, 36% (intervention group) and 36% (control group) of participants were between 50 and 64 years old. In <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>, the mean age of participants was 44 (range 19–71) years in the intervention group and 46 (range 19–79) years in the control group. </p> <p>In <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>, the participants in both groups had, on average, one comorbidity, most frequently past or current history of asthma (16% in budesonide arm versus 14% in control arm). In <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, 80% of participants in each group (intervention group and control group) had one or more comorbidity. The most common comorbidity was high blood pressure requiring therapy in 45% participants. Ten percent of study participants had lung disease. The most common comorbidity in <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> was arterial hypertension (23.9% of participants in intervention group and 20.7% of participants in the control group). In this, more people in the intervention group had type 2 diabetes mellitus and asthma than in the control group (diabetes mellitus: 11.2% in the intervention group versus 3.9% in the control group; P = 0.007; asthma: 9.1% in the intervention group versus 3.9% in the control group; P = 0.042). </p> <p>Participants were randomised in a median of six days in <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> and three days in <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>. In <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>, the duration of symptoms prior to randomisation was not reported. However, the participants had to have a positive SARS‐CoV‐2 PCR or antigen diagnostic sample obtained in the previous 72 hours prior to randomisation. The most common symptoms in the SARS‐CoV‐2 concurrent randomisation population in <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> were feeling unwell (96.6%), cough (84.2%), myalgia (75.6%), shortness of breath (58.3%), and fever (51.9%). In <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>, it was cough (79% in the intervention group versus 70% in the control group), fever (70% in the intervention group versus 64% in the control group), and headache (57% in the intervention group versus 55% in the control group). In contrast to <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, shortness of breath had evolved only in 16% of the participants in each study arm, myalgia in 9% (intervention group) and 16% (control group). <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> did not report the details of the symptoms at baseline. </p> </section> <section id="CD015125-sec-0062"> <h5 class="title">Interventions and comparators</h5> <p>Two studies compared budesonide plus standard care versus standard care alone (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). Budesonide was administered as a dry powder inhaler (Pulmicort Turbuhaler, AstraZeneca, Gothenburg, Sweden) at a dose of 400 μg per actuation (two puffs to be taken twice per day; total dose 1600 μg). In <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, the participants administered budesonide for 14 days, while in <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>, they were asked to stop taking the inhaler when they felt they had recovered (self‐reported symptom recovery) or if they achieved the primary outcome (COVID‐19‐related urgent care visits, including emergency department assessment or hospitalisation). As result, 79.9% of participants randomised to budesonide in this study reported taking budesonide for at least seven days. </p> <p><a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> compared ciclesonide metered‐dose inhaler (MDI) in addition to standard care to placebo plus standard care. Ciclesonide was administered in a dose of 160 μg per actuation, two actuations twice a day (total daily dose 640 μg). The duration of the therapy was 30 days. Placebo was not further specified in this study. </p> <p>Standard care in <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> included antipyretics for symptoms of fever (products containing paracetamol, or non‐steroidal anti‐inflammatory drugs such as aspirin and ibuprofen) and honey for symptoms of cough. In <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, standard care was specified as antipyretics and antibiotics if bacterial pneumonia was suspected. The concomitant therapy in <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> included mostly antipyretics and only in a few cases antibiotics (5% of participants) and antivirals (1% of participants). Neutralising monoclonal antibodies were given only in one participant in the intervention group. </p> </section> <section id="CD015125-sec-0063"> <h5 class="title">Outcomes</h5> <p>The primary outcome in <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> was defined as COVID‐19‐related urgent care visits, including emergency department assessment or hospitalisation. <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> had two co‐primary endpoints measured within 28 days of randomisation: time to first reported recovery, defined as the first instance that a participant reported feeling recovered; and hospitalisation or death related to COVID‐19. In <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>, secondary outcomes included clinical recovery, defined by self‐reported time to symptom resolution; viral symptoms measured by the Common Cold Questionnaire (CCQ) 12 and the InFLUenza Patient‐Reported Outcome (FLUPro)13 questionnaire; blood oxygen saturations and body temperature; and SARS‐CoV‐2 viral load. In <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, secondary outcomes included the rating of how well participants felt (scale 1 to 10), time to sustained recovery, early sustained recovery, time to initial alleviation of symptoms, time to sustained alleviation of symptoms, time to initial reduction of severity of symptoms, contacts with health services, hospital assessment without admission, oxygen administration, ICU admission, mechanical ventilation, and WHO‐5 Well‐Being Index. </p> <p>In <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>, the primary endpoint was time to alleviation of all COVID‐19‐related symptoms (cough, dyspnoea, chills, feeling feverish, repeated shaking with chills, muscle pain, headache, sore throat, and new loss of taste or smell) by day 30 as self‐reported in the participant's eDiary. Secondary endpoints included subsequent emergency department visits or hospital admissions for reasons attributable to COVID‐19, incidence of hospital admissions or death, all‐cause mortality, COVID‐19‐related mortality, impact on the time to hospital admission or death compared with placebo plus standard supportive care, alleviation of all COVID‐19‐related symptoms by days seven, 14, and 30 as well as additional secondary outcomes such as oxygen saturation levels, COVID‐19 viral load, and safety assessments. </p> </section> <section id="CD015125-sec-0064"> <h5 class="title">Studies awaiting classification</h5> <p>We found five study registries with inhaled corticosteroids: two studies "completed" (<a href="./references#CD015125-bbs2-0005" title="AlsultanM , ObeidA , AlsamarraiO , AnanMT , BakrA , SolimanN , et al.Efficacy of colchicine and budesonide in improvement outcomes of patients with coronavirus infection 2019 in Damascus, Syria: a randomised control trial. Interdisciplinary Perspectives on Infectious Diseases2021;2021:1-7. ">Alsultan 2021</a>; <a href="./references#CD015125-bbs2-0006" title="EUCTR2020-001616-18-ES.Treatment with inhaled corticoids in patients with COVID-19 admitted to hospital with pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001616-18 (first received 23 June 2021). NCT04355637.Inhaled corticosteroid treatment of COVID-19 patients with pneumonia. www.clinicaltrials.gov/ct2/show/NCT04355637 (first received 23 June 2021). ">EUCTR2020‐001616‐18‐ES/NCT04355637</a>), two studies terminated for insufficient recruitment (<a href="./references#CD015125-bbs2-0007" title="NCT04331054.Protective role of inhaled steroids for Covid-19 infection (INHASCO). clinicaltrials.gov/ct2/show/NCT04331054 (first received 29 March 2020). ">NCT04331054</a>; <a href="./references#CD015125-bbs2-0008" title="NCT04435795.Inhaled ciclesonide for outpatients with COVID19 (CONTAIN). clinicaltrials.gov/ct2/show/NCT04435795 (first received 16 June 2020). ">NCT04435795</a>), and one study with a preprint including results (<a href="./references#CD015125-bbs2-0009" title="SongJY , YoonJG , SeoYB , LeeJ , EomJS , LeeJS , et al.Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomised, open-label, phase 2 trial. Journal of Clinical Medicine2021;10(16):3545. [DOI: 10.3390/jcm10163545]">Song 2021</a>). See <a href="#CD015125-tbl-0003">Table 2</a>. </p> <div class="table" id="CD015125-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of studies awaiting classification</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor/developer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0005" title="AlsultanM , ObeidA , AlsamarraiO , AnanMT , BakrA , SolimanN , et al.Efficacy of colchicine and budesonide in improvement outcomes of patients with coronavirus infection 2019 in Damascus, Syria: a randomised control trial. Interdisciplinary Perspectives on Infectious Diseases2021;2021:1-7. ">Alsultan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: expired or transmitted to ICU during the first 24 hours</p> <p>Included: oxygen saturation ≤ 93%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide + supportive care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supportive care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0006" title="EUCTR2020-001616-18-ES.Treatment with inhaled corticoids in patients with COVID-19 admitted to hospital with pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001616-18 (first received 23 June 2021). NCT04355637.Inhaled corticosteroid treatment of COVID-19 patients with pneumonia. www.clinicaltrials.gov/ct2/show/NCT04355637 (first received 23 June 2021). ">EUCTR2020‐001616‐18‐ES/NCT04355637</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundacion Clinic per a la Recerca Biomédica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted for pneumonia (status #3 and #4 OMS scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0007" title="NCT04331054.Protective role of inhaled steroids for Covid-19 infection (INHASCO). clinicaltrials.gov/ct2/show/NCT04331054 (first received 29 March 2020). ">NCT04331054</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assistance Publique – Hôpitaux de Paris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised, but not admitted to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SYMBICORT RAPIHALER + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (insufficient recruitment)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0008" title="NCT04435795.Inhaled ciclesonide for outpatients with COVID19 (CONTAIN). clinicaltrials.gov/ct2/show/NCT04435795 (first received 16 June 2020). ">NCT04435795</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>McGill University Health Centre/Research Institute of the McGill University Health Centre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic adults positive by PCR for COVID‐19 within 5 days of enrolment with fever, cough, or shortness of breath </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide intranasal and inhaled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (could not meet target enrolment)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0009" title="SongJY , YoonJG , SeoYB , LeeJ , EomJS , LeeJS , et al.Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomised, open-label, phase 2 trial. Journal of Clinical Medicine2021;10(16):3545. [DOI: 10.3390/jcm10163545]">Song 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Research Foundation of Korea (NRF) grant [2020M3A9I2081699] and Korea University Guro Hospital grant (I2000171) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low National Early Warning Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide + hydroxychloroquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Setting unclear; no data for ciclesonide alone vs standard care</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>COVID‐19: coronavirus disease 2019; ICU: intensive care unit; PCR: polymerase chain reaction; RCT: randomised controlled trial. </p> </div> </div> <p><a href="./references#CD015125-bbs2-0006" title="EUCTR2020-001616-18-ES.Treatment with inhaled corticoids in patients with COVID-19 admitted to hospital with pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001616-18 (first received 23 June 2021). NCT04355637.Inhaled corticosteroid treatment of COVID-19 patients with pneumonia. www.clinicaltrials.gov/ct2/show/NCT04355637 (first received 23 June 2021). ">EUCTR2020‐001616‐18‐ES/NCT04355637</a> had planned to include 300 participants with moderate COVID‐19. Participants were treated with budesonide plus standard care and compared to participants treated with standard care (with/without placebo – unclear registry entry classifying the study as "open‐label" but with the use of a placebo). <a href="./references#CD015125-bbs2-0009" title="SongJY , YoonJG , SeoYB , LeeJ , EomJS , LeeJS , et al.Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomised, open-label, phase 2 trial. Journal of Clinical Medicine2021;10(16):3545. [DOI: 10.3390/jcm10163545]">Song 2021</a> compared ciclesonide plus hydroxychloroquine to standard care and ciclesonide versus standard care in 61 participants with unclear indication for hospitalisation. For the comparison ciclesonide versus standard care, the study did not provide any data. The publication only provided data for participants in the intervention arm partly receiving a combination of ciclesonide and hydroxychloroquine, so that the observed effect cannot be attributed to the corticosteroids with certainty. </p> <p>We contacted the authors of <a href="./references#CD015125-bbs2-0006" title="EUCTR2020-001616-18-ES.Treatment with inhaled corticoids in patients with COVID-19 admitted to hospital with pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001616-18 (first received 23 June 2021). NCT04355637.Inhaled corticosteroid treatment of COVID-19 patients with pneumonia. www.clinicaltrials.gov/ct2/show/NCT04355637 (first received 23 June 2021). ">EUCTR2020‐001616‐18‐ES/NCT04355637</a>, <a href="./references#CD015125-bbs2-0013" title="JRCTs031190269.A multicenter, open-label, randomised controlled phase II study to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 (RACCO trial). jrct.niph.go.jp/en-latest-detail/jRCTs031190269 (first received 27 March 2020). Terada-HirashimaJ , SuzukiM , UemuraY , HojoM , MikamiA , SugiuraW , et al.Efficacy and safety of inhaled ciclesonide in treating patients with asymptomatic or mild COVID-19 in the RACCO trial: protocol for a multicenter, open-label, randomised controlled trial. JMIR Research Protocols2020;9(12):e23830. ">JRCTS031190269</a>, and <a href="./references#CD015125-bbs2-0009" title="SongJY , YoonJG , SeoYB , LeeJ , EomJS , LeeJS , et al.Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomised, open-label, phase 2 trial. Journal of Clinical Medicine2021;10(16):3545. [DOI: 10.3390/jcm10163545]">Song 2021</a> via email to obtain data from participants of interest but have not yet received a reply. </p> </section> <section id="CD015125-sec-0065"> <h5 class="title">Ongoing studies</h5> <p>We identified 10 ongoing RCTs that compared inhaled corticosteroids versus standard care or placebo; see <a href="#CD015125-tbl-0004">Table 3</a>. Five studies were classified as "recruiting" or "ongoing" and the remaining five as "not yet recruiting", according to the study registration data. These 10 trials intend to recruit 4114 participants: 1426 participants with mild COVID‐19 and 2688 participants with moderate COVID‐19. </p> <div class="table" id="CD015125-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of ongoing studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor/developer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0014" title="NCT04193878.Arrest respiratory failure from pneumonia (ARREST). clinicaltrials.gov/ct2/show/record/NCT04193878 (first received 10 December 2019). ">NCT04193878</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stanford University</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe pneumonia defined as hospitalisation for acute (&lt; 7 days) onset of symptoms (cough, sputum production, or dyspnoea) and radiographic evidence of pneumonia by chest radiograph or CT scan and evidence of systemic inflammation (temperature &lt; 35 °C or &gt; 38 °C or WBC count &gt; or &lt; upper or lower limits for site or procalcitonin &gt; 0.5 μg/L), or known current immunosuppression preventing inflammatory response AND hypoxaemia defined as new requirement for supplemental oxygen with oxygen saturation &lt; 90% on room air, ≤ 96% on ≥ 2 L/minute oxygen, or &gt; 6 L/minute or NIV (regardless of oxygen saturation) at enrolment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol + budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enrolling by invitation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0016" title="NCT04381364.Inhalation of ciclesonide for patients with COVID-19: a randomised open treatment study (HALT COVID-19) (HALT). clinicaltrials.gov/ct2/show/NCT04381364 (first received 23 June 2021). ">NCT04381364</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ola Blennow, St Goran's Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with PCR‐positive SARS‐CoV‐2 receiving supplemental oxygen therapy with start &lt; 48 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0017" title="NCT04937543.Efficacy of inhaled therapies in the treatment of acute symptoms associated with COVID-19 (TRIVID). clinicaltrials.gov/ct2/show/NCT04937543 (first received 31 August 2021). ">NCT04937543</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UPECLIN HC FM Botucatu Unesp</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with PCR‐positive SARS‐CoV‐2 with arterial pulse oximetry (oxygen saturation) saturation ≥ 92% in room air </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclomethasone + standard care; beclomethasone/formoterol/glycopyrronium + standard care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0015" title="NCT04356495.Trial of COVID-19 outpatient treatment in individuals with risk factors for aggravation (COVERAGEFrance). clinicaltrials.gov/ct2/show/record/NCT04356495 (first received 11 April 2020). ">NCT04356495</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University Hospital, Bordeaux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SARS‐CoV‐2‐confirmed cases with absence of criteria for hospitalisation or oxygen therapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0013" title="JRCTs031190269.A multicenter, open-label, randomised controlled phase II study to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 (RACCO trial). jrct.niph.go.jp/en-latest-detail/jRCTs031190269 (first received 27 March 2020). Terada-HirashimaJ , SuzukiM , UemuraY , HojoM , MikamiA , SugiuraW , et al.Efficacy and safety of inhaled ciclesonide in treating patients with asymptomatic or mild COVID-19 in the RACCO trial: protocol for a multicenter, open-label, randomised controlled trial. JMIR Research Protocols2020;9(12):e23830. ">JRCTS031190269</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SARS‐CoV‐2‐positive cases with no apparent pneumonia due to COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0010" title="CTRI/2020/04/024948.A clinical trial to study the effects of hydroxychloroquine, ciclesonide and ivermectin in treatment of moderate COVID-19 illness. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=43364&amp;EncHid=&amp;modid=&amp;compid=%27,%2743364det%27 (first received 30 April 2020). ">CTRI/2020/04/024948</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lady Hardinge Medical College</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of moderate COVID‐19 disease as defined by presence of pneumonia (clinical and radiological signs) with respiratory rate 15–30/minute or oxygen saturation 90–94% on room air (or both). PCR throat swab‐positive patients and contacts of confirmed COVID‐19 cases will be considered as a COVID‐19 case </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0011" title="CTRI/2020/10/028581.Clinical trial to study the effect of budesonide taken through inhalation in mild COVID cases. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=47042&amp;EncHid=&amp;modid=&amp;compid=%27,%2747042det%27 (first received 23 October 2020). ">CTRI/2020/10/028581</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dr Tushar Patel, SPARSH Chest Disease Centre, 100B Swastik Society, Opposite Samved Hospital, Navrangpura, Ahmedabad </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic people with mild symptoms of &lt; 5 days of duration;</p> <p>oxygen saturation &gt; 94% at room air</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0012" title="EUCTR2020-002208-37-DK.CIMMCov: a randomised clinical study for prevention of severe disease in mild-to-moderate COVID-19 patients, using the inhaled medication ciclesonide. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002208-37 (first received 8 June 2020). ">EUCTR2020‐002208‐37‐DK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory Research Unit 237, Hvidovre Hospital, Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People admitted to a COVID‐19 emergency department &lt; 24 hours due to COVID‐19‐like symptoms </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0018" title="NCT05054322.FLuticasone in cOvid Treatment (FLOT). clinicaltrials.gov/ct2/show/NCT05054322 (first received 20 September 2021). ">NCT05054322</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Medicine and Pharmacy at Ho Chi Minh City</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Having COVID‐related symptoms within 5 days prior to randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0019" title="NCT05055414.Arformoterol/budesonide for COVID-19. clinicaltrials.gov/ct2/show/NCT05055414 (first received 16 September 2021). ">NCT05055414</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea United Pharm. Inc.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New onset of symptoms suggestive of COVID‐19 (fever, cough, sore throat, etc.) or diagnosed with COVID‐19 within 7 days of participant being seen at visit 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, probably outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide/arformoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>COVID‐19: coronavirus disease 2019; CT: computer tomography; NIV: non‐invasive ventilation; PCR: polymerase chain reaction; RCT: randomised controlled trial; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; WBC: white blood cell. </p> </div> </div> <p>Five RCTs are designed to study the effect of ciclesonide, two of which will compare ciclesonide plus standard care versus standard care alone, one versus vitamin D, one versus placebo (both in addition to standard care), and one study does not define a comparator. </p> <p>Three studies are designed to study budesonide: one RCT will compare budesonide plus formoterol plus standard care versus placebo plus standard care, one budesonide plus standard care versus standard care alone, and one budesonide plus arformoterol plus standard care versus placebo plus standard care. </p> <p>The only study that investigates inhaled fluticasone in addition to standard care compares it against the standard care alone (<a href="./references#CD015125-bbs2-0018" title="NCT05054322.FLuticasone in cOvid Treatment (FLOT). clinicaltrials.gov/ct2/show/NCT05054322 (first received 20 September 2021). ">NCT05054322</a>). </p> <p>One study compares beclomethasone or beclomethasone‐formoterol‐glycopyrronium plus standard care with standard care alone (<a href="./references#CD015125-bbs2-0017" title="NCT04937543.Efficacy of inhaled therapies in the treatment of acute symptoms associated with COVID-19 (TRIVID). clinicaltrials.gov/ct2/show/NCT04937543 (first received 31 August 2021). ">NCT04937543</a>). </p> </section> </section> <section id="CD015125-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded one study that did not meet our inclusion criteria as it designated the route of application as inhaled, but it was topical (<a href="./references#CD015125-bbs2-0004" title="IRCT20200522047542N1.Effect of inhaled corticosteroids in the treatment of anosmia in patients with COVID-19. en.irct.ir/trial/48379 (first received 23 June 2021). ">IRCT20200522047542N1</a>). </p> </section> </section> <section id="CD015125-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias for three RCTs that contributed 13 study results to nine outcomes for outpatient participants (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>; <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). </p> <p>The completed RoB 2 tool with responses to all assessed signalling questions is available online at: <a href="https://zenodo.org/record/6334453#.YiX55nrMJPZ" target="_blank">https://zenodo.org/record/6334453#.YiX55nrMJPZ</a>. </p> <section id="CD015125-sec-0068"> <h4 class="title">Overall judgements for studies that included people with a confirmed diagnosis of moderate‐to‐severe COVID‐19 </h4> <p>We found no studies with people with a confirmed diagnosis of moderate‐to‐severe COVID‐19.</p> </section> <section id="CD015125-sec-0069"> <h4 class="title">Overall judgements for studies that included people with a confirmed diagnosis of asymptomatic SARS‐CoV‐2 infection or mild COVID‐19 </h4> <section id="CD015125-sec-0070"> <h5 class="title">Overall risk of bias by study</h5> <p>From 13 study results, we rated six (46%) at low risk of bias, six (46%) at high risk of bias, and we had concerns for one study. Regarding the respective studies, from <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> four low and two high risk results were included, from <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> one high risk and one of some concerns and from <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> two low risk and three high risk. </p> </section> <section id="CD015125-sec-0071"> <h5 class="title">Overall risk of bias by outcome</h5> <section id="CD015125-sec-0072"> <h6 class="title">Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo) </h6> <p>We judged admission to hospital or death, adverse events and infections at low risk across studies. For the outcome all‐cause mortality, two of three studies were at low risk of bias and one study with some concerns due to missing prespecification of the outcome (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>). The following outcomes received high risk of bias judgements: symptom resolution: all initial symptoms resolved at day 14 (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>), symptom resolution: all initial symptoms resolved at day 30 (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>), symptom resolution: mean time to recovery (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>), quality of life (<a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>) and serious adverse events (<a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>) due to measurement of the outcome and selection of the reported result. In case of unblinded study design and subjective outcomes, risk of bias was high (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). Also, the withdrawal of consent after randomisation in an open‐label study is likely to be due to the experimental context. Two outcomes in one study were added only after the conduction of the study and not part of the initial outcome set in the study registration (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>). </p> </section> </section> </section> </section> <section id="CD015125-sec-0073"> <h3 class="title" id="CD015125-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD015125-tbl-0001"><b>Summary of findings 1</b> Inhaled corticosteroids plus standard care compared to standard care (with or without placebo) for adults with a confirmed diagnosis of mild COVID‐19</a> </p> <section id="CD015125-sec-0074"> <h4 class="title">People with confirmed diagnosis of moderate‐to‐severe COVID‐19</h4> <p>We found no RCTs reporting outcomes for people with moderate‐to‐severe disease treated with inhaled corticosteroids. </p> </section> <section id="CD015125-sec-0075"> <h4 class="title">People with a confirmed diagnosis of asymptomatic SARS‐CoV‐2 infection or mild COVID‐19</h4> <p>We found no RCTs reporting outcomes for people with asymptomatic SARS‐CoV‐2 infection.</p> <p>All included participants had a confirmed diagnosis of COVID‐19 and mild symptoms according to <a href="./references#CD015125-bbs2-0047" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al.A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>'s WHO clinical progression scale. </p> <section id="CD015125-sec-0076"> <h5 class="title">Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo) </h5> <p>The evidence profile is presented in <a href="./full#CD015125-tbl-0001">summary of findings Table 1</a>. Regarding missing participant data, we judged all study results presented below at low risk of bias in domain 3 and assumed missingness at random in line with our methods without further investigation. Missing outcome data affected quality of the evidence for serious adverse events and adverse events. </p> <section id="CD015125-sec-0077"> <h6 class="title">All‐cause mortality at up to day 30</h6> <p>Three studies with 2132 participants reported data on all‐cause mortality (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>; <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). For two studies, the observation period was 28 days (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>), and for one study, it was 30 days (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>). Overall, 6/1057 participants in the intervention group died compared to 10/1075 participants in the control group. Inhaled corticosteroids may result in little to no difference in all‐cause mortality up to day 30 (RR 0.61, 95% CI 0.22 to 1.67; 9 deaths per 1000 in the control group versus 6 deaths per 1000 (95% CI 2 to 16 deaths per 1000) in the intervention group; random‐effects model; I<sup>2</sup> not applicable;low‐certainty evidence; Analysis 1.1). We downgraded the certainty of evidence from high to low due to very serious imprecision (very low number of events, wide CI). </p> <section id="CD015125-sec-0078"> <p><b>Subgroup analyses</b></p> <p>There were insufficient data to conduct subgroup analyses taking into account sociodemographic characteristics (e.g. sex, age, ethnicity), comorbidities, different dosages, different timings, and vaccination status. The setting of all three studies was primary care in high‐income countries, therefore, no subgroup analysis related to these factors was possible. </p> </section> <section id="CD015125-sec-0079"> <p><b>Sensitivity analyses</b></p> <p>We summarised the effects of sensitivity analyses in <a href="#CD015125-tbl-0005">Table 4</a>. As in <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> and <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>, no participant had died, there was no difference in the overall effect estimate when we compared the fixed‐effect versus random‐effects model or excluded the preprint <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>. As we found only a low risk of bias or some concerns in our included RCTs for this outcome, there was no opportunity to exclude studies at high risk of bias for sensitivity analysis (see <a href="#CD015125-tbl-0005">Table 4</a>). Across all studies, approximately 5% of data were missing, but this was balanced between study arms. Due to the low number of missing data, we did not perform a sensitivity analysis. </p> <div class="table" id="CD015125-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analyses for the comparison: inhaled corticosteroids plus standard care versus standard care with or without placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analyses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bias (excluding studies at high risk of bias)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect vs random‐effects model</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Preprint vs journal publication</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61, 95% CI 0.22 to 1.67; 3 studies, 2132 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61, 95% CI 0.22 to 1.67; 3 studies, 2132 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61, 95% CI 0.22 to 1.67; 3 studies, 2132 participants</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.</p> </div> </div> </section> </section> <section id="CD015125-sec-0080"> <h6 class="title">Admission to hospital or death within 30 days</h6> <p>Two studies with 2025 participants reported data on admission to hospital or death (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). Inhaled corticosteroids probably reduce the admission to hospital or occurrence of death up to day 30 (RR 0.72, 95% CI 0.51 to 0.99; 79 events per 1000 in the control group versus 57 events per 1000 (95% CI 40 to 78 events per 1000) in the intervention group; random‐effects model; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD015125-fig-0003" title="">Analysis 1.2</a>). We downgraded the certainty of evidence from high to moderate due to serious imprecision (calculation of the optimal information size for an 80% power: 3764 participants would have been needed). </p> </section> <section id="CD015125-sec-0081"> <h6 class="title">Symptom resolution: all initial symptoms resolved (asymptomatic) at day 14</h6> <p>Two studies with 1986 participants reported data on all initial symptoms resolved at day 14 (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). Inhaled corticosteroids probably increase symptom resolution at day 14 (RR 1.19, 95% CI 1.09 to 1.30; 465 events per 1000 in the control group versus 553 events per 1000 (95% CI 507 to 605 events per 1000) in the intervention group; random‐effects model; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD015125-fig-0004" title="">Analysis 1.3</a>). We downgraded the certainty of evidence from high to moderate for serious risk of bias. </p> </section> <section id="CD015125-sec-0082"> <h6 class="title">Symptom resolution: mean time to recovery (days)</h6> <p><a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> reported a mean time to recovery for 129 participants. While the mean time in the budesonide group was 8 (SD 5) days, the standard care group needed 12 (SD 8) days. Inhaled corticosteroids may decrease the duration of symptom resolution (MD −4 days, 95% CI −6.22 to −1.78 days; 139 participants; random‐effects model; I<sup>2</sup> not applicable; low‐certainty evidence; <a href="./references#CD015125-fig-0005" title="">Analysis 1.4</a>). Our main reasons for downgrading were serious risk of bias (one level) due to the very subjective outcome measured in an open‐label study, and serious imprecision (one level) given the low number of participants. </p> <p><a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> reported the median time to recovery of 19 days (interquartile range (IQR) 14 to 21) for the ciclesonide group and 19 days (IQR 16 to 23) for the placebo group. As this study did not report the mean data, we did not include the results in the meta‐analyses. </p> </section> <section id="CD015125-sec-0083"> <h6 class="title">Symptom resolution: all initial symptoms resolved (asymptomatic) at day 30</h6> <p>One study with 400 participants reported data on all initial symptoms resolved at day 30 (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>). Overall, 139/197 participants in the intervention group felt recovered of all initial symptoms compared to 129/203 participants in the control group (RR 1.11, 95% CI 0.97 to 1.27; random‐effects model; I<sup>2</sup> not applicable; <a href="./references#CD015125-fig-0006" title="">Analysis 1.5</a>). </p> </section> <section id="CD015125-sec-0084"> <h6 class="title">Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) up to 28 days </h6> <p><a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> with 1434 participants reported quality of life at 28 days on the WHO‐5 Well‐Being Questionnaire with scores ranging from 0 to 100 (MD 2.60, 95% CI 0.02 to 5.18; random‐effects model; I<sup>2</sup> not applicable; <a href="./references#CD015125-fig-0007" title="">Analysis 1.6</a>). </p> </section> <section id="CD015125-sec-0085"> <h6 class="title">Serious adverse events during the study period</h6> <p>One study with 1586 participants reported data on serious adverse events (<a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). Overall, 2/787 participants in the intervention group had a serious adverse event compared to 4/799 participants in the control group. The evidence is very uncertain about the effect of inhaled corticosteroids on serious adverse events (RR 0.51, 95% CI 0.09 to 2.76; 5 events per 1000 in the control group versus 3 events per 1000 (95% CI 0 to 14 events per 1000) in the intervention group; I<sup>2</sup> not applicable; random‐effects model; very low‐certainty evidence; <a href="./references#CD015125-fig-0008" title="">Analysis 1.7</a>). We downgraded the certainty of evidence from high to very low for very serious imprecision due to a very low number of events and a wide CI and for serious risk of bias as the other two studies did not report serious adverse events (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>; <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>). </p> </section> <section id="CD015125-sec-0086"> <h6 class="title">Adverse events (any grade) up to day 30</h6> <p>One study with 400 participants reported data on adverse events (any grade) (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>). Overall, 22/197 participants in the intervention group had an adverse event compared to 29/203 participants in the control group. Inhaled corticosteroids may result in little to no difference in adverse events (RR 0.78, 95% CI 0.47 to 1.31; 143 events per 1000 in the control group versus 111 events per 1000 (95% CI 67 to 187 events per 1000) in the intervention group; I<sup>2</sup> not applicable; random‐effects model; low‐certainty evidence; <a href="./references#CD015125-fig-0009" title="">Analysis 1.8</a>). We downgraded the certainty of evidence from high to low due to serious imprecision with a low number of events/participants and wide CI and for serious risk of bias as the other two studies did not report adverse events or did not report them in an adequate manner (<a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>; <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>). </p> <p><a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> reported five adverse events for 146 participants; all in the intervention arm. The manner of reporting suggests that only treatment‐related adverse events or side effects were reported. Therefore, we did not include the results in a meta‐analysis. </p> </section> <section id="CD015125-sec-0087"> <h6 class="title">Infections during the study period</h6> <p>One study with 400 participants reported data on infections (<a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>). Overall, 6/197 participants in the intervention group had an infection compared to 7/203 participants in the control group. Inhaled corticosteroids may result in little to no difference in infections (RR 0.88, 95% CI 0.30 to 2.58; 34 events per 1000 in the control group versus 30 events per 1000 (95% CI 10 to 89 events per 1000) in the intervention group; I<sup>2</sup> not applicable; random‐effects model; low‐certainty evidence; <a href="./references#CD015125-fig-0010" title="">Analysis 1.9</a>). We downgraded the certainty of evidence from high to low for very serious imprecision due to very low number of events and wide CI. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015125-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015125-sec-0088"></div> <section id="CD015125-sec-0089"> <h3 class="title" id="CD015125-sec-0089">Summary of main results</h3> <p>We aimed to assess the efficacy and safety of inhaled corticosteroids for the treatment of COVID‐19. We found no studies for people with asymptomatic infection or confirmed diagnosis of COVID‐19 and moderate‐to‐severe disease. </p> <p>For people with a confirmed diagnosis of COVID‐19 and mild disease, we identified three RCTs (3607 participants) evaluating inhaled corticosteroids compared to standard care (with or without placebo). Two RCTs (3207 participants) compared budesonide plus standard care to standard care alone, of which we analysed all cases with PCR‐confirmed diagnosis and being concurrently randomised (1625 participants), and one RCT (400 participants) compared ciclesonide plus standard care to standard care plus placebo. </p> <p> <ul id="CD015125-list-0038"> <li> <p>Inhaled corticosteroids may result in little to no difference in all‐cause mortality in outpatients with mild COVID‐19 (low‐certainty evidence). We could not explore differences in the effect of inhaled corticosteroids based on sex, comorbidities, different timing, and different dosage due to insufficient data. </p> </li> <li> <p>Inhaled corticosteroids probably reduce the risk of admission to hospital or death at up to day 30 (moderate‐certainty evidence). Further, the intervention probably increases the resolution of all initial symptoms at day 14 and may decrease the duration to symptoms resolved (low‐certainty evidence). </p> </li> <li> <p>Regarding adverse events and infections, inhaled corticosteroids may result in little to no difference, and the certainty of evidence was low for both outcomes. In terms of serious adverse events, the evidence is very uncertain about the effect of inhaled corticosteroids (very‐low certainty evidence). </p> </li> </ul> </p> </section> <section id="CD015125-sec-0090"> <h3 class="title" id="CD015125-sec-0090">Overall completeness and applicability of evidence</h3> <p>The included studies were conducted in high‐income countries with 2171 participants in our analyses. The numbers available for analysis ranged between 139 and 2132 owing to availability of data. All studies investigated participants with mild disease in outpatient settings. Currently, there is no evidence for people with asymptomatic SARS‐CoV‐2 infection or inpatients with moderate‐to‐severe disease. </p> <p>For our main efficacy outcomes, mortality and admission to hospital or death, the overall event rate was very low (less than 1% for mortality, less than 10% for admission to hospital or death), resulting in low‐ to moderate‐certainty evidence and very small differences in effects between the intervention and control group. In two of three RCTs, there were no deaths. We do not expect the evidence to change in the near future because completed but unpublished studies awaiting classification would only yield data on about 700 participants while our review is already comprising more than 2000 participants. Furthermore, the applicability of the evidence is unlikely to be enhanced by the ongoing studies that address similar populations and medicines to the studies we already have. Due to the living character of this review, it will be updated as soon as new relevant evidence arises. </p> <p>With regard to diagnostic workup and timing of the intervention, we chose to analyse only those participants who had laboratory‐confirmed SARS‐CoV‐2 infection, and who had been allocated to intervention and control arms at the same time. This meant that we excluded a large amount of data from <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>. We assumed that testing is feasible in almost every setting where the intervention would be available. It is likely that changes in epidemiology, legislation, standard care, and respective media coverage have occurred over time. This could affect the outcomes of interest in this review. </p> <p>The weight of <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> in the meta‐analyses of mortality, hospital admission or death, and symptom resolution ranged from 88% to 100%. Given the large weight of this study, the generalisability of the review is influenced by the characteristics of the participants: aged 50 to 64 years with comorbidities or aged 65 years and older irrespective of comorbidities. However, participants who were unable to use the inhaler appropriately were excluded. This means that direct evidence can only be derived for people within this certain age group excluding the younger people (aged less than 50 years) and any people unable to use an inhaler. No prior use of inhaled corticosteroids was allowed, meaning that participants had no long‐term experience with how to use an inhaler correctly. This might have consequences on potential benefits and harms of the inhaler and the medicine it delivers, although it should be noted that the risk of systemic adverse effects is likely to be negligible even with poor inhaler technique (swallowing) because of the favourable pharmacokinetics of budesonide with low oral bioavailability and especially ciclesonide owing to its on‐site activation (<a href="./references#CD015125-bbs2-0026" title="DerendorfH , NaveR , DrollmannA , CerasoliF , WurstW .Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. European Respiratory Journal2006;28(5):1042-50. [DOI: 10.1183/09031936.00074905]">Derendorf 2006</a>). </p> <p><a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> and <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> administered budesonide using the Pulmicort Turbuhaler device, which might not be readily available worldwide. Moreover, ciclesonide, the corticosteroid intervention in <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>, is still protected by a patent and not available as a generic drug. Hence, both availability and pricing might be a barrier to its use on a global scale (<a href="./references#CD015125-bbs2-0030" title="Use of ciclesonide for the treatment of respiratory diseases. patents.google.com/patent/US8371292B2/en (accessed 28 October 2021).">Google Patent Overview Ciclesonide</a>). </p> <p>Moreover, the timing of the recruitment periods of the included studies may be affected by rapidly emerging knowledge in epidemiology and therapeutic interventions. Most data in this review has been collected before spring 2021 (<a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>: 27 November 2020 to 31 March 2021; <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a>: 11 June 2020 to 3 November 2020; <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>: 16 July 2020 to 9 December 2020). Consequently, most participants were not fully vaccinated (13% received one dose and 1% received the second dose in <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>, and no vaccinations in <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> and <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a>). Even if the absolute number of patients with mild disease and a severe course of COVID‐19 can be reduced through vaccination, we currently assume that the effects shown in the investigated population are also valid for fully vaccinated patients showing symptoms (i.e. WHO grade 3 or 4). </p> <p>In contrast to SARS‐CoV‐2‐specific monoclonal antibodies, inhaled corticosteroids do not directly interact with the spike protein of the virus, and so different variants of the virus are unlikely to influence the potential benefits and harms of the inhaled corticosteroids. The delta variant of SARS‐CoV‐2 is more virulent than its predecessors, but pathogenicity appears to be similar or even favourable to the evaluated intervention. Together with the pleiotropic immunomodulatory effect of corticosteroids, we assume that in contrast to more targeted therapies also in future variants, evidence can be seen as direct. Delta variant virus particles have been shown in vitro to have a higher ACE2 receptor affinity and increased infectivity caused by a change in antigenic properties (<a href="./references#CD015125-bbs2-0051" title="MotozonoC , ToyodaM , ZahradnikJ , SaitoA , NasserH , TanTS , et al.SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe2021;29(7):1124-36. [DOI: doi.org/10.1016/j.chom.2021.06.006]">Motozono 2021</a>). The variant evades cellular immunity and increases infectivity. From this perspective, a reduction of the expression of the ACE2 receptor, which is postulated for inhaled corticosteroids (<a href="./references#CD015125-bbs2-0028" title="FinneyLJ , GlanvilleN , FarneH , AniscenkoJ , FenwickP , KempSV , et al.Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. Journal of Allergy and Clinical Immunology2021;147(2):510-9. [DOI: doi:10.1016/j.jaci.2020.09.034]">Finney 2021</a>; <a href="./references#CD015125-bbs2-0053" title="PetersMC , SajuthiS , DefordP , ChristensonS , RiosCL , MontgomeryMT , et al.COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. American Journal of Respiratory and Critical Care Medicine2020;202:83-90. [DOI: 10.1164/rccm.202003-0821OC]">Peters 2020</a>), could be a promising mechanism of action against the delta variant of SARS‐CoV‐2. However, the potential enhanced effect needs to be verified in future RCTs. </p> </section> <section id="CD015125-sec-0091"> <h3 class="title" id="CD015125-sec-0091">Quality of the evidence</h3> <section id="CD015125-sec-0092"> <h4 class="title">Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo) </h4> <p>We included data from three RCTs in the analysis of efficacy and safety of inhaled corticosteroids. The population of interest was people with a confirmed diagnosis of mild COVID‐19. </p> <p>We rated the certainty of the evidence as moderate to very low (see <a href="./full#CD015125-tbl-0001">summary of findings Table 1</a>). We downgraded the certainty of evidence due to risk of bias arising from the unblinded study design for all patient‐reported outcomes. However, we acknowledge that within trial platforms such as PRINCIPLE (<a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>), blinding is difficult to implement. Low number of events/imprecision affected all endpoints except symptom resolution at day 14 and led to downgrading by one point. In addition, missing safety outcome data (adverse events and serious adverse events) led to downgrading for reporting bias. At least the latter issue could easily be improved in future publications. </p> </section> </section> <section id="CD015125-sec-0093"> <h3 class="title" id="CD015125-sec-0093">Potential biases in the review process</h3> <p>To avoid potential biases in the review process we did all steps in duplicate (e.g. screening search results, data extraction, bias assessment, assessing certainty using the GRADE approach) and had intense discussions involving both clinicians and methodologists to agree on data analyses and interpretation. As the definition of clinical outcomes such as symptom resolution varied across included studies it is highly relevant to involve clinical experts, not to misinterpret data. </p> <p>In addition to peer‐reviewed, full‐text articles, we also included one preprint. The results of the sensitivity analyses did not differ between with or without preprint. We are aware of the potentially lower quality of preprint publications, and that results could change once the peer‐reviewed journal publications are available. In cases of missing data, we contacted study authors for additional data or relevant details if we needed more information. However, we have not yet received an answer. We are confident that we identified all relevant studies and will monitor ongoing studies as well as full publications of preprints closely after the publication of this review. </p> <p>Since only a few data (about 5%) were missing across all studies, we do not expect this to result in a risk of bias. </p> </section> <section id="CD015125-sec-0094"> <h3 class="title" id="CD015125-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>We could not find current published RCT‐based peer‐reviewed systematic reviews focussing on inhaled corticosteroids in people without prior use. Apart from that, one the regularly updated living guideline for people with confirmed COVID‐19 of 24 September 2021 did not include the intervention (<a href="./references#CD015125-bbs2-0079" title="Therapeutics and COVID-19: living guideline. www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.1 (accessed 22 February 2022). [https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.3]">WHO 2021d</a>). One living systematic review published in March 2021 only included the preprint of <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> without further mention of inhaled corticosteroids (<a href="./references#CD015125-bbs2-0061" title="SiemieniukRA , BartoszkoJJ , GeL , ZeraatkarD , IzcovichA , KumE , et al.Drug treatments for COVID-19: living systematic review and network meta-analysis (latest update). BMJ2020;370(1):m2980. [DOI: 10.1136/bmj.m2980]">Siemieniuk 2020</a>). </p> <p>One living network meta‐analysis includes budesonide as an intervention, using data from <a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> and <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> in the analysis of mortality and clinical progression (<a href="./references#CD015125-bbs2-0023" title="Pharmacologic treatments for COVID-19 patients – budesonide. covid-nma.com/living_data/index.php?treatment1=budesonide&amp;submit=Validate#comparisons_div (accessed 26 October 2021).">COVID‐NMA 2021</a>). Notably, they seemed to have included participants without laboratory‐confirmed testing or from asynchronous allocation from <a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a>. The different choice of the cohort for analysis comes with implications for directness and applicability of the evidence. Irrespective of this different approach, <a href="./references#CD015125-bbs2-0023" title="Pharmacologic treatments for COVID-19 patients – budesonide. covid-nma.com/living_data/index.php?treatment1=budesonide&amp;submit=Validate#comparisons_div (accessed 26 October 2021).">COVID‐NMA 2021</a> assessed the certainty of the evidence similarly to our review. The main differences were to outcomes related to the different populations from the same included studies and the exclusion of the <a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> preprint. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015125-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD015125-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015125-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 1: All‐cause mortality at up to day 30" data-id="CD015125-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 1: All‐cause mortality at up to day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015125-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 2: Admission to hospital or death at up to 30 days" data-id="CD015125-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 2: Admission to hospital or death at up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015125-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 3: Symptom resolution: all initial symptoms resolved (asymptomatic) at day 14" data-id="CD015125-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 3: Symptom resolution: all initial symptoms resolved (asymptomatic) at day 14 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015125-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 4: Symptom resolution: mean time to recovery (days)" data-id="CD015125-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 4: Symptom resolution: mean time to recovery (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015125-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 5: Symptom resolution: all initial symptoms resolved at up to day 30" data-id="CD015125-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 5: Symptom resolution: all initial symptoms resolved at up to day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015125-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 6: Quality of life at day 28: mean in well‐being (WHO‐5 Well‐Being Questionnaire)" data-id="CD015125-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 6: Quality of life at day 28: mean in well‐being (WHO‐5 Well‐Being Questionnaire) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015125-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 7: Serious adverse events" data-id="CD015125-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 7: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015125-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 8: Adverse events" data-id="CD015125-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 8: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015125-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/urn:x-wiley:14651858:media:CD015125:CD015125-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 9: Infections" data-id="CD015125-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_t/tCD015125-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo), Outcome 9: Infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015125/media/CDSR/CD015125/image_n/nCD015125-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015125-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Inhaled corticosteroids plus standard care compared to standard care (with or without placebo) for adults with a confirmed diagnosis of mild COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Inhaled corticosteroids plus standard care compared to standard care (with or without placebo) for adults with a confirmed diagnosis of asymptomatic SARS‐CoV‐2 infection or mild COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> inhaled corticosteroids plus standard care </p> <p><b>Comparison:</b> standard care (with or without placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with standard care (with or without placebo)<sup>a</sup> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with inhaled corticosteroids (plus standard care)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: at up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> <p>(2 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.61</b> </p> <p>(0.22 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2132</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids may result in little to no difference in all‐cause mortality up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Admission to hospital or death</b> </p> <p>Follow‐up: at up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> <p>(40 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b> </p> <p>(0.51 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2025</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖</p> <p><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids probably reduce the risk of admission to hospital or death up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom resolution:</b> all initial symptoms resolved </p> <p>at day 14</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>465 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000</p> <p>(507 to 605)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> </p> <p>(1.09 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊖</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids probably increase the resolution of all initial symptoms at day 14. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom resolution:</b> duration to symptoms resolved </p> <p>Follow‐up: at up to day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration to symptoms resolved was 12.00 days.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of symptoms resolved was 8.00 days (5.78 to 10.22 days).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −4.00</b> days </p> <p>(−6.22 to −1.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids may decrease the duration to symptom resolution.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: during study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> <p>(0 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b> </p> <p>(0.09 to 2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1586</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊖⊖⊖</p> <p><b>Very Low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of inhaled corticosteroids on serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: at up to day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> <p>(67 to 187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> </p> <p>(0.47 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids may result in little to no difference in adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infections</b> </p> <p>Follow‐up: during study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> <p>(10 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> </p> <p>(0.30 to 2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊖⊖</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled corticosteroids may result in little to no difference in infections.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention group (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE working group grades evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimated from included studies (with 10% of participants being vaccinated at least once).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (very low number of events, wide CI).<br/><sup>c</sup>Downgraded one level for serious imprecision (low number of participants/events and optimal information size would be 3764 participants).<br/><sup>d</sup>Downgraded one level for serious risk of bias (partly measurement of the outcome affected by unblinded design, selection of the reported result, missing outcome data as the safety‐relevant outcome was not reported) and reporting bias (the safety‐relevant outcome was not reported).<br/><sup>e</sup>Downgraded one level for serious imprecision (low number of participants/events and wide CI). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Inhaled corticosteroids plus standard care compared to standard care (with or without placebo) for adults with a confirmed diagnosis of mild COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015125-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies for the comparison: inhaled corticosteroid plus standard care versus standard care (with or without placebo)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to steroids and analysed in this review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to control and analysed in this review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity at randomisation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0001" title="ClemencyBM , VarugheseR , Gonzalez-RojasY , MorseCG , PhipatanakulW , KosterDJ , et al.A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. medRxiv2021:1-24. [DOI: doi.org/10.1101/2021.09.07.21261811]">Clemency 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide 160 μg per actuation, 2 actuations twice daily (total daily dose 640 μg) + standard care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants had an oxygen saturation of ≥ 93% on room air; had ≥ 1 of the following symptoms of COVID‐19: fever, cough, or dyspnoea </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0002" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine2021;9(7):763-72. [DOI: doi.org/10.1016/S2213-2600(21)00160-0]RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al.Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv2021:1-25. [DOI: doi.org/10.1101/2021.02.04.21251134]STOIC Patient information sheet. stoic.ndm.ox.ac.uk/patient-information-sheet (accessed prior to 22/02/2022). ">Ramakrishnan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide, 400 µg per actuation (2 puffs twice daily; total dose 1600 µg) + standard care (antipyretics and honey) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With symptoms of COVID‐19 (new‐onset cough and fever or anosmia, or both) within 7 days </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0003" title="YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv2021:1-43. [DOI: doi.org/10.1101/2021.04.10.21254672]YuLM , BafadhelM , DorwardJ , HaywardG , SavilleBR , GbinigieO , et al.Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;398(10301):1-13. [DOI: doi.org/10.1016/S0140-6736(21)01744-X]">Yu 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide 800 µg twice daily + standard care for 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>787 (analysed concurrent and SARS‐CoV‐2‐positive population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>838 (analysed concurrent andSARS‐CoV‐2‐positive population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, platform trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing symptoms of confirmed or suspected COVID‐19 (high temperature or new, continuous cough or change in sense of smell/taste, or a combination of these) within 14 days </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>RCT: randomised controlled trial; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies for the comparison: inhaled corticosteroid plus standard care versus standard care (with or without placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015125-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of studies awaiting classification</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor/developer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0005" title="AlsultanM , ObeidA , AlsamarraiO , AnanMT , BakrA , SolimanN , et al.Efficacy of colchicine and budesonide in improvement outcomes of patients with coronavirus infection 2019 in Damascus, Syria: a randomised control trial. Interdisciplinary Perspectives on Infectious Diseases2021;2021:1-7. ">Alsultan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: expired or transmitted to ICU during the first 24 hours</p> <p>Included: oxygen saturation ≤ 93%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide + supportive care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supportive care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0006" title="EUCTR2020-001616-18-ES.Treatment with inhaled corticoids in patients with COVID-19 admitted to hospital with pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001616-18 (first received 23 June 2021). NCT04355637.Inhaled corticosteroid treatment of COVID-19 patients with pneumonia. www.clinicaltrials.gov/ct2/show/NCT04355637 (first received 23 June 2021). ">EUCTR2020‐001616‐18‐ES/NCT04355637</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundacion Clinic per a la Recerca Biomédica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted for pneumonia (status #3 and #4 OMS scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0007" title="NCT04331054.Protective role of inhaled steroids for Covid-19 infection (INHASCO). clinicaltrials.gov/ct2/show/NCT04331054 (first received 29 March 2020). ">NCT04331054</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assistance Publique – Hôpitaux de Paris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised, but not admitted to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SYMBICORT RAPIHALER + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (insufficient recruitment)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0008" title="NCT04435795.Inhaled ciclesonide for outpatients with COVID19 (CONTAIN). clinicaltrials.gov/ct2/show/NCT04435795 (first received 16 June 2020). ">NCT04435795</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>McGill University Health Centre/Research Institute of the McGill University Health Centre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic adults positive by PCR for COVID‐19 within 5 days of enrolment with fever, cough, or shortness of breath </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide intranasal and inhaled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (could not meet target enrolment)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0009" title="SongJY , YoonJG , SeoYB , LeeJ , EomJS , LeeJS , et al.Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomised, open-label, phase 2 trial. Journal of Clinical Medicine2021;10(16):3545. [DOI: 10.3390/jcm10163545]">Song 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National Research Foundation of Korea (NRF) grant [2020M3A9I2081699] and Korea University Guro Hospital grant (I2000171) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low National Early Warning Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide + hydroxychloroquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Setting unclear; no data for ciclesonide alone vs standard care</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>COVID‐19: coronavirus disease 2019; ICU: intensive care unit; PCR: polymerase chain reaction; RCT: randomised controlled trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of studies awaiting classification</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015125-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of ongoing studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor/developer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0014" title="NCT04193878.Arrest respiratory failure from pneumonia (ARREST). clinicaltrials.gov/ct2/show/record/NCT04193878 (first received 10 December 2019). ">NCT04193878</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stanford University</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe pneumonia defined as hospitalisation for acute (&lt; 7 days) onset of symptoms (cough, sputum production, or dyspnoea) and radiographic evidence of pneumonia by chest radiograph or CT scan and evidence of systemic inflammation (temperature &lt; 35 °C or &gt; 38 °C or WBC count &gt; or &lt; upper or lower limits for site or procalcitonin &gt; 0.5 μg/L), or known current immunosuppression preventing inflammatory response AND hypoxaemia defined as new requirement for supplemental oxygen with oxygen saturation &lt; 90% on room air, ≤ 96% on ≥ 2 L/minute oxygen, or &gt; 6 L/minute or NIV (regardless of oxygen saturation) at enrolment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol + budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enrolling by invitation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0016" title="NCT04381364.Inhalation of ciclesonide for patients with COVID-19: a randomised open treatment study (HALT COVID-19) (HALT). clinicaltrials.gov/ct2/show/NCT04381364 (first received 23 June 2021). ">NCT04381364</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ola Blennow, St Goran's Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with PCR‐positive SARS‐CoV‐2 receiving supplemental oxygen therapy with start &lt; 48 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0017" title="NCT04937543.Efficacy of inhaled therapies in the treatment of acute symptoms associated with COVID-19 (TRIVID). clinicaltrials.gov/ct2/show/NCT04937543 (first received 31 August 2021). ">NCT04937543</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UPECLIN HC FM Botucatu Unesp</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with PCR‐positive SARS‐CoV‐2 with arterial pulse oximetry (oxygen saturation) saturation ≥ 92% in room air </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclomethasone + standard care; beclomethasone/formoterol/glycopyrronium + standard care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0015" title="NCT04356495.Trial of COVID-19 outpatient treatment in individuals with risk factors for aggravation (COVERAGEFrance). clinicaltrials.gov/ct2/show/record/NCT04356495 (first received 11 April 2020). ">NCT04356495</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University Hospital, Bordeaux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SARS‐CoV‐2‐confirmed cases with absence of criteria for hospitalisation or oxygen therapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0013" title="JRCTs031190269.A multicenter, open-label, randomised controlled phase II study to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 (RACCO trial). jrct.niph.go.jp/en-latest-detail/jRCTs031190269 (first received 27 March 2020). Terada-HirashimaJ , SuzukiM , UemuraY , HojoM , MikamiA , SugiuraW , et al.Efficacy and safety of inhaled ciclesonide in treating patients with asymptomatic or mild COVID-19 in the RACCO trial: protocol for a multicenter, open-label, randomised controlled trial. JMIR Research Protocols2020;9(12):e23830. ">JRCTS031190269</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SARS‐CoV‐2‐positive cases with no apparent pneumonia due to COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0010" title="CTRI/2020/04/024948.A clinical trial to study the effects of hydroxychloroquine, ciclesonide and ivermectin in treatment of moderate COVID-19 illness. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=43364&amp;EncHid=&amp;modid=&amp;compid=%27,%2743364det%27 (first received 30 April 2020). ">CTRI/2020/04/024948</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lady Hardinge Medical College</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of moderate COVID‐19 disease as defined by presence of pneumonia (clinical and radiological signs) with respiratory rate 15–30/minute or oxygen saturation 90–94% on room air (or both). PCR throat swab‐positive patients and contacts of confirmed COVID‐19 cases will be considered as a COVID‐19 case </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0011" title="CTRI/2020/10/028581.Clinical trial to study the effect of budesonide taken through inhalation in mild COVID cases. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=47042&amp;EncHid=&amp;modid=&amp;compid=%27,%2747042det%27 (first received 23 October 2020). ">CTRI/2020/10/028581</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dr Tushar Patel, SPARSH Chest Disease Centre, 100B Swastik Society, Opposite Samved Hospital, Navrangpura, Ahmedabad </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic people with mild symptoms of &lt; 5 days of duration;</p> <p>oxygen saturation &gt; 94% at room air</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0012" title="EUCTR2020-002208-37-DK.CIMMCov: a randomised clinical study for prevention of severe disease in mild-to-moderate COVID-19 patients, using the inhaled medication ciclesonide. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002208-37 (first received 8 June 2020). ">EUCTR2020‐002208‐37‐DK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory Research Unit 237, Hvidovre Hospital, Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People admitted to a COVID‐19 emergency department &lt; 24 hours due to COVID‐19‐like symptoms </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0018" title="NCT05054322.FLuticasone in cOvid Treatment (FLOT). clinicaltrials.gov/ct2/show/NCT05054322 (first received 20 September 2021). ">NCT05054322</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Medicine and Pharmacy at Ho Chi Minh City</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Having COVID‐related symptoms within 5 days prior to randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015125-bbs2-0019" title="NCT05055414.Arformoterol/budesonide for COVID-19. clinicaltrials.gov/ct2/show/NCT05055414 (first received 16 September 2021). ">NCT05055414</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea United Pharm. Inc.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind, RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New onset of symptoms suggestive of COVID‐19 (fever, cough, sore throat, etc.) or diagnosed with COVID‐19 within 7 days of participant being seen at visit 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, probably outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide/arformoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>COVID‐19: coronavirus disease 2019; CT: computer tomography; NIV: non‐invasive ventilation; PCR: polymerase chain reaction; RCT: randomised controlled trial; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; WBC: white blood cell. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of ongoing studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015125-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analyses for the comparison: inhaled corticosteroids plus standard care versus standard care with or without placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analyses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bias (excluding studies at high risk of bias)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect vs random‐effects model</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Preprint vs journal publication</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61, 95% CI 0.22 to 1.67; 3 studies, 2132 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61, 95% CI 0.22 to 1.67; 3 studies, 2132 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61, 95% CI 0.22 to 1.67; 3 studies, 2132 participants</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analyses for the comparison: inhaled corticosteroids plus standard care versus standard care with or without placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/full#CD015125-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015125-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality at up to day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.22, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Admission to hospital or death at up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.51, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Symptom resolution: all initial symptoms resolved (asymptomatic) at day 14 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.09, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Symptom resolution: mean time to recovery (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Symptom resolution: all initial symptoms resolved at up to day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Quality of life at day 28: mean in well‐being (WHO‐5 Well‐Being Questionnaire) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Inhaled corticosteroids (plus standard care) versus standard care (with or without placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#CD015125-tbl-0006">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality at up to day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Clemency 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low as the randomisation process was adequate because it is done remotely and moreover consider concealment adequate. Slight baseline differences were most likely due to chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Deviations were balanced and most likely not due to the trial context in this double‐blinded trial. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Although there were around 5% of participants lost to follow‐up, it seems not probable that the outcome has been affected relevantly by those dropouts. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged low risk of bias, scheduled contact at day 30.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low due to pre‐specification of the outcome.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Ramakrishnan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stratified block randomisation, sequence held in secure network location at Oxford University, characteristics incl. SARS‐CoV‐2 status are well balanced. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low due to only a low number of participants withdrew consent.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low due to a small number of missing data. In the intervention group about 1% and in the control group about 4% of the participants withdrew consent due to the allocation. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low because the measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged some concerns because the outcome was not pre‐specified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall we judged some concerns due to missing pre‐specification of the outcome.</p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based Sortition and the allocation sequence was intimated to GP and patient via email/letter. There are no baseline differences that would suggest a problem with randomisation </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged risk of bias low because there were no reported deviations from intended interventions. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low because it is not likely that missingness in the outcome depended on its true value. There were about 5% of the participants without a diary entry. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low because the measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data were in accordance with the protocol, so that we assessed this domain low.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality at up to day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Admission to hospital or death at up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Clemency 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low as the randomisation process was adequate because it is done remotely and moreover consider concealment adequate. Slight baseline differences were most likely due to chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Deviations were balanced and most likely not due to the trial context in this double‐blinded trial. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Although there were around 5% of participants lost to follow‐up, it seems not probable that the outcome has been affected relevantly by those dropouts. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged low risk of bias, scheduled contact at day 30.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low due to pre‐specification of the outcome.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based Sortition and the allocation sequence was intimated to GP and patient via email/letter. There are no baseline differences that would suggest a problem with randomisation </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged risk of bias low because there were no reported deviations from intended interventions. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low because it is not likely that missingness in the outcome depended on its true value. There were about 5% of the participants without a diary entry. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low because the measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data were in accordance with the protocol, so that we assessed domain 5 low.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Admission to hospital or death at up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Symptom resolution: all initial symptoms resolved (asymptomatic) at day 14</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Clemency 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low as the randomisation process was adequate because it is done remotely and moreover consider concealment adequate. Slight baseline differences were most likely due to chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Deviations were balanced and most likely not due to the trial context in this double‐blinded trial. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Although there were around 5% of participants lost to follow‐up, it seems not probable that the outcome has been affected relevantly by those dropouts. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged low risk of bias, as the combination of structured contacts and eDiary provided a high probability that the outcome would be detected. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain high due to a subsequent addition of this outcome to the trial protocol month after having completed the trial. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged high risk of bias due to subsequent addition of this outcome (probably during the analysis process). </p> </td> </tr> <tr class="study-data"> <td> <p>Yu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based Sortition and the allocation sequence was intimated to GP and patient via email/letter. There are no baseline differences that would suggest a problem with randomisation </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged risk of bias low because there were no reported deviations from intended interventions. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low because it is not likely that missingness in the outcome depended on its true value. There were about 5% of the participants without a diary entry. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain high because it is likely that the knowledge of the intervention has influenced the subjective self‐assessment of this outcome. Missing placebo control could introduce relevant confounding to subjective self‐assessment of this endpoint. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data were in accordance with the protocol, so that we assessed domain 5 low.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged high risk of bias due to measurement of the outcome. This introduces potential high risk of bias towards the experimental. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Symptom resolution: all initial symptoms resolved (asymptomatic) at day 14</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Symptom resolution: mean time to recovery (days)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ramakrishnan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stratified block randomisation, sequence held in secure network location at Oxford University, characteristics incl. SARS‐CoV‐2 status are well balanced. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low due to only a low number of participants withdrew consent</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low due to no evidence of relevant missing data. In the intervention group about 1% and in the control group about 4% of the participants withdrew consent due to the allocation. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain high due to the unanswered question when are the participants considered recovered and the outcome is very subjective. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain some concerns because the outcome was not pre‐specified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged high risk of bias due to the unanswered question when are the participants considered recovered and the subjective perspective of the outcome. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Symptom resolution: mean time to recovery (days)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Symptom resolution: all initial symptoms resolved at up to day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Clemency 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low as the randomisation process was adequate because it is done remotely and moreover consider concealment adequate. Slight baseline differences were most likely due to chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Deviations were balanced and most likely not due to the trial context in this double‐blinded trial. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Although there were around 5% of participants lost to follow‐up, it seems not probable that the outcome has been affected relevantly by those dropouts. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged low risk of bias, as the combination of structured contacts and eDiary provided a high probability that the outcome would be detected. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain high due to a subsequent addition of this outcome to the trial protocol month after having completed the trial. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged high risk of bias due to subsequent addition of this outcome (probably during the analysis process). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Symptom resolution: all initial symptoms resolved at up to day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Quality of life at day 28: mean in well‐being (WHO‐5 Well‐Being Questionnaire)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Yu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based Sortition and the allocation sequence was intimated to GP and patient via email/letter. There are no baseline differences that would suggest a problem with randomisation </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged risk of bias low because there were no reported deviations from intended interventions. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low because it is not likely that missingness in the outcome depended on its true value. There were about 5% of the participants without a diary entry. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain high because it is likely that the knowledge of the intervention has influenced the subjective self‐assessment of this outcome. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data were in accordance with the protocol, so that we assessed domain 5 low.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged high risk of bias due to measurement of the outcome.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Quality of life at day 28: mean in well‐being (WHO‐5 Well‐Being Questionnaire)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Yu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based Sortition and the allocation sequence was intimated to GP and patient via email/letter. There are no baseline differences that would suggest a problem with randomisation </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged risk of bias low because there were no reported deviations from intended interventions. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low because it is not likely that missingness in the outcome depended on its true value. There were about 5% of the participants without a diary entry. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain high because it is likely that the knowledge of the intervention has influenced the subjective self‐assessment of this outcome. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data were in accordance with the protocol, so that we assessed domain 5 low.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged high risk of bias due to measurement of the outcome.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Clemency 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low as the randomisation process was adequate because it is done remotely and moreover consider concealment adequate. Slight baseline differences were most likely due to chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Deviations were balanced and most likely not due to the trial context in this double‐blinded trial. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some adverse events lead to trial discontinuation. But they had been reported, so we do not assume, that the ~5% "lost to follow up" affected the outcome. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged low risk of bias, as the combination of structured contacts and eDiary provided a high probability that the outcome would have been detected. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low due to pre‐specification of the outcome.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Infections</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Clemency 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low as the randomisation process was adequate because it is done remotely and moreover consider concealment adequate. Slight baseline differences were most likely due to chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Deviations were balanced and most likely not due to the trial context in this double‐blinded trial. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Although there were around 5% of participants lost to follow‐up, it seems not probable that the outcome has been affected relevantly by those dropouts. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged low risk of bias, as the combination of structured contacts and eDiary provided a high probability that the outcome would be detected. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low due to pre‐specification of the outcome.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015125/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015125&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015125-note-0017">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015125-note-0048">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015125-note-0068">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015125-note-0043">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD015125-note-0038">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD015125-note-0063">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD015125-note-0027">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD015125-note-0037">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD015125-note-0073">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD015125-note-0032">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD015125-note-0022">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015125-note-0053">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015125-note-0058">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015125\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015125"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015125\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015125\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015125"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015125\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015125"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015125\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015125\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015125"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015125&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015125';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015125/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015125/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015125%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716898212"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015125/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716898215"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015125/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918daabdbbe61be3',t:'MTc0MDcxNjg5OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 